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 Research suggests that medication adherence among individuals with mental 
health problems is problematic. The issue of medication non-adherence among this 
population is consistent among the different mental health diagnoses. Numerous factors 
contribute to medication non-adherence: patient issues, service delivery issues, and issues 
related to the measurement of medication adherence, which lacks a gold standard. This 
dissertation is a compendium of three manuscripts that represent three distinct but related 
studies on medication adherence among individuals with mental health challenges.  
 The first manuscript is an integrative review that seeks to assess the validity, 
reliability, and levels of evidence of existing instruments for measuring medication 
adherence in patients with schizophrenia. The second is another integrative review that 
examines literature in the past decade (2006-2016) on the use of mobile phone contacts 
(MPC) in individuals with severe mental illness to improve medication adherence after 
hospital discharge. The third, a descriptive correlational study, examines mental health 
services (MHS) users’ preferred MPC delivery method when receiving support to 
increase medication adherence after discharge.  
 The findings from the first integrative review show the importance of validating 
medication adherence measures in this population. Findings from the second show the 
extent to which MPC support the increase of medication adherence in this population.  
Findings from the third show the importance of identifying patients’ preferences for an 
MPC method when providing support to increase medication adherence in this 
population. The findings of the two integrative reviews and the descriptive correlational 
study are integrated at the conclusion of the dissertation.
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Medication adherence in patients with mental illness is a major public health 
concern.  Medication nonadherence causes rapid disease progression, increased disease 
complications, poorer functional outcomes, lower quality of life (Najt, PFusar-Poli, and 
Brambilla, 2011; Novick et al., 2010), increased violent behavior (Van Dorn, Volavka, 
and Johnson, 2012), increased suicide attempts (Novick et al., 2010), and earlier/more 
frequent re-hospitalization (Brown, Bennett, Li, and Bellack, 2011; Najt, PFusar-Poli, 
and Brambilla, 2011). Social support is noted to be important for patient recovery 
(Bickley et al., 2013; Sawant and Jethwani 2010); however, challenges that come with 
mental illnesses disrupt   these supportive networks (Green et al., 2002). This lack of 
support affects the individuals with mental health challenges especially when faced with 
barriers such as lack of transportation, difficulties in making medical decisions, managing 
personal health problems, and troubling mental health symptoms (Nath et al., 2012) after 
discharge. This can lead to poor adherence or non-adherence after discharge from the 
hospital, causing a revolving door.  
One major gap in trying to address medication adherence in this population is the 
need to find a gold standard to measure medication adherence for these patients. 
Measuring medication adherence is important to both researchers and clinicians because 
inaccurately measuring adherence in this population can lead to several potentially costly 
and dangerous problems (Lam and Fresco, 2015) such as judging an effective treatment 
as ineffective and using unnecessary expensive diagnostic procedures (Lam and Fresco, 
2015). An extensive literature search of studies between 2000 to 2016 regarding the 
reliability and validity of existing measures for medication adherence identified six 
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studies that used fourteen instruments specifically measuring medication 
adherence in this population. Even though these instruments are still relevant in 
measuring medication adherence for patients with mental illnesses no study serves as a 
gold standard because the scales reported in each study lacked either validity, reliability 
or sensitivity. 
Studies show that about 50% of individuals with SMI become non-adherent in 
managing their treatment the first month following discharge from the hospital, which is 
a major factor influencing acute psychiatric hospital readmission (Tomko et al., 2013).  
Increased non-adherence to prescribed medications after discharge leads to failure of 
follow-up care after discharge, failure to achieve the full benefits of treatment (Lee et al., 
2015), and higher mental health care costs (Pantalon et al., 2014). Technology has shown 
potential benefits to persons with mental health challenges (Palmier-Claus et al., 2013; 
Ho, 2003) especially mobile technology (West, 2012). Telecommunications technology is 
worldwide (International Telecommunication Union 2013), feasible (Nieuwlaat et al., 
2014), and can benefit healthcare (Chen, Mishara, and Liu, 2010; Palmier-Claus et al., 
2013).  
Mobile phone usage in individuals with mental health challenges is proportionate 
to the general population’s use (70% to 100%) (Miller et al 2015; Ennis et at., 2012), and 
patients acknowledge its benefits to healthcare delivery (Palmier-Claus et al., 2013). 
Mobile phone contact is seen as having the potential for increasing medication adherence 
in individuals with mental health challenges.  A thorough literature search between 2006 
to 2016 showed only five studies had occurred the use of mobile phone contacts to 
increase medication adherence in individuals with severe mental illness after discharge. 
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Although these studies showed that mobile phone contact increases medication 
adherence in this population (Montes et al., 2012; Beebe, Smith and Phillips 2014; Beebe 
et al., 2008; Granholm et al., 2012), many limitations with the studies have been 
identified.  Mental health researchers have yet to adequately research the use of mobile 
phone technology to increase medication adherence in this population; thus, the potential 
of mobile technology use to improve mental health services among individuals with 
serious mental illness remains uncertain (Ben-Zeev et al., 2013). 
Furthermore, none of the studies reviewed explicitly used a theoretical 
framework, although the core domains of social support theory are implied. The reviewed 
studies showed that individuals with SMI were given tangible aid and services, advice, 
suggestions, and a variety of information including information for self-evaluation, as 
described by Glanz, Rimer and Viswanath (2008). Using the social support theory to 
increase medication adherence was important for organizing research design and 
methods, explaining study results, and placing the findings within the context of science 
(Mock et al., 2007; Radwin and Fawcett, 2002). This was described in the second 
manuscript. Social support theory postulates that social support may have positive effects 
on the physical, mental, and social health of an individual (Glanz, Rimer and Viswanath 
2008).  
Manuscripts 
This dissertation includes three distinct but related manuscripts. The first and 
second manuscripts are integrative reviews. The first integrative review gives a detailed 
assessment of the validity, reliability, and levels of evidence for existing instruments that 
measure medication adherence in patients with schizophrenia. The second integrative 
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review identifies studies that used text messages and phone calls to increase 
medication adherence in individuals with mental health challenges. The third manuscript, 
a descriptive correlational study, identifies mental health service users preferred mobile 





Beebe, L., Smith, K. D., & Phillips, C.  (2014). A comparison of telephone and texting 
interventions for persons with schizophrenia spectrum disorders. Issues in Mental 
Health Nursing, 35, 323–329 
Ben-Zeev, D., Davis, K. E., Kaiser, S., Krzsos, I., & Drake, R. E. (2013). Mobile 
technologies among people with serious mental illness: opportunities for future 
services. Administration and Policy in Mental Health and Mental Health Services 
Research, 40, 340–343. 
Bickley, H., Hunt, I. M., Windfuhr, K., Shaw, J., Appleby, L., & Kapur, N. (2013). 
Suicide within two weeks of discharge from psychiatric inpatient care: a case-
control study. Psychiatric Services 64, 653-659. 
Brown, C.H., Bennett, M.E., Li, L., & Bellack, A. S. (2011). Predictors of initiation and 
engagement in substance abuse treatment among individuals with co-occurring 
serious mental illness and substance use disorders. Addictive Behaviors, 36, 439-
447. 
Chen, H., Mishara, B.L., & Liu, X.X. (2010). A pilot study of mobile telephone message 
interventions with suicide attempters in China. The Journal of Crisis Intervention 
and Suicide Prevention, 31, 109-112 
Glanz, K., Rimer, B., & Viswanath, K. (2008). Health behavior and health education, 
theory, research, and practice (4th ed.). San Francisco: Jossey-Bass. 
Granholm, E., Ben-Zeev, D., Link, P.C., Bradshaw, K. R., & Holden, J. L. (2012). Mobile 
Assessment and Treatment for Schizophrenia (MATS): A pilot trial of an 
6	
	
interactive text-messaging intervention for medication adherence, socialization, 
and auditory hallucinations. Schizophrenia Bulletin, 38, 414–42538 
Ho, T. P. (2003). The suicide risk of discharged psychiatric patients. Journal of Clinical 
Psychiatry, 64, 702–707. 
Lam, W. Y. & Fresco, P. (2015). Medication adherence measures: an overview. BioMed 
Research International, 2015 
Lee, S. Y., Kim, K. H., Kim, T., Kim, S. M., Kim, J.W., Han, C., Song, J. Y., & Paik, 
J.W. (2015). Outpatient follow-up visit after hospital discharge lowers risk of 
re-hospitalization in patients with schizophrenia: A nationwide population-based 
study. Psychiatry Investigation, 12, 425–433. 
Mock, V., St. Ours, C., Hall, S., Bositis, A., Tillery, M., Belcher, A., . . . McCorkle,R. 
(2007). Using a conceptual model in nursing research -mitigating fatigue in 
cancer patients. Journal of Advanced Nursing, 58, 503-512. 
Montes, J. M., Medina, E., Gomez-Beneyto, M., & Maurino, J., (2012). A short message 
services (SMS)-based strategy for enhancing adherence to antipsychotic 
medication in schizophrenia. Psychiatry Research, 200, 89–95.  
Nath, S., Wong, Y., Marcus, S., & Solomon, P. (2012). Predictors of health 
servicesutilization among persons with psychiatric disabilities engaged in 
supported independent housing. Psychiatric Rehabilitation Journal, 35, 315-323.  
Najt, P., Fusar-Poli, P., & Brambilla, P. (2011). Co-occurring mental and substance abuse 




Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keepanasseril, A., ... 
Haynes, R. B. (2014). Interventions for enhancing medication adherence. 
Cochrane Database of Systematic Reviews, 20, 11.  
Novick, D., Haro, J.M., Suarez, D., Perez, V., Dittmann, R.W., & Haddad, P.M. (2010). 
Predictors and clinical consequences of non-adherence with antipsychotic 
medication in the outpatient treatment of schizophrenia. Psychiatry Research, 
176, 109–113. 
Palmier-Claus, J.E., Rogers, A., Ainsworth, J., Machin, M., Barrowclough, C., Laverty, 
L., … Lewis, S. W. (2013).  Integrating mobile-phone based assessment for 
psychosis into people’s everyday lives and clinical care: a qualitative study. BMC 
Psychiatry,	13, 1. 
Radwin, L., & Fawcett, J. (2002). A conceptual model-based programme of nursing 
research retrospective and prospective applications. Journal of Advanced Nursing, 
40, 355-360. 
Sawant, N. S. & Jethwani K.S. (2010). Understanding family functioning and social 
support in unremitting schizophrenia: A study in India. Indian J Psychiatry, 52, 
145-9. 
Tomko, J. R., Ahmed N., Mukherjee, K., Roma, R. S., DiLucente D., & Orchowski, K. 
(2013). Evaluation of a discharge medication service on an acute psychiatric unit. 
Hospital Pharmacy, 48, 314–320. 
Van Dorn, R., Volavka, J., & Johnson, N. (2012). Mental disorder and violence: is there a 
relationship beyond substance use? Social Psychiatry and Psychiatric 





Measuring Medication Adherence in Patients with Schizophrenia: An Integrative Review. 
Bright C. E. (2016): Measuring Medication Adherence in Patients with Schizophrenia: 





The purpose of this paper is to assess the validity, reliability and levels of evidence of 
existing instruments for measuring medication adherence in patients with schizophrenia. 
Background 
Schizophrenia is estimated to affect approximately 7 individuals out of 1000 in their 
lifetimes, with fifty percent of patients attempting suicide. However, studies have shown 
that measuring medication adherence in patients with schizophrenia is difficult and no 
gold standard currently exists. Without reliable and valid instruments to evaluate non-
adherence in this population, research into strategies to improve adherence cannot move 
forward. 
Data Sources 
This integrative review used the following search terms: assessing, measuring, 
medication adherence, schizophrenia, medication non-adherence, validity, reliability and 
measures. Databases searched included CINAHL, PubMed, PsycINFO and Scopus). 
Studies were included if they were published from 2000 to 2016. Fourteen instruments 
were identified from six studies and were included in this review. 
Results 
All the instruments assessed were weak in both validity and reliability coupled with 
having low levels of evidence. Three instruments (two are fairly new) yielded better 
validity, reliability and sensitivity; however, they have not been assessed in broad, 
diverse samples, so their generalizability remains unclear. 
Conclusion 
This study suggests the need to develop an instrument with adequate validity, reliability, 





Nonadherence among patients with severe mental illness has been estimated to be 
between 30% and 65% (Yang et al., 2012). Non-adherence has substantial impact on 
disease progression, complications, functional outcomes and quality of life (Najt, 
Fusar-Poli, & Brambilla, 2011; Novick et al., 2010), leading to relapses, 
re-hospitalizations (Brown, Bennett, Li, & Bellack, 2011; Lacro, Dunn, Dolder, 
Leckband, & Jeste, 2002; Leucht & Heres, 2006; Trivedi, Lin, & Katon, 2007), and even 
death (Meltzer, Anand, & Alphs, 2000). Medication non-adherence poses a formidable 
challenge to behavioral health clinicians (Glazer, 2010) and increases the economic 
burden on the healthcare system and society (Brian, 2016; Cloutier et al., 2016; Dilla, 
Ciudad, & Alvarez, 2013; Insel, Schoenbaum, & Wang, 2009; Mackin, Delucchi, 
Bennett, & Areán, 2011; Pantalon, Murphy, Barry, Lavery, & Swanson, 2014). 
Schizophrenia is chronic and disabling, affecting thinking, feelings, actions and 
movement (catatonia). Schizophrenia is estimated to affect approximately 7 individuals 
out of 1000 in their lifetimes (Higashi, Medic, Littlewood, Granström, & Hert, 2013), 
with increased risk of suicide (Leucht & Heres, 2006; Lindstrom, Eriksson, & Levander, 
2012) as fifty percent of patients attempt suicide (Fields, 2011). Anti-psychotic 
medications are the cornerstone for treatment of schizophrenia (Buchanan et al., 
2010;Velligan et al., 2009) but as many as 50% of patients with schizophrenia fail to take 
their medications as prescribed (Lacro et al., 2002; Stephenson et al., 2012; Velligan et 
al., 2009) and non-adherence rate accounts for 40% of re-hospitalizations (Knapp, King, 
Pugner, & Lapuerta, 2004) noted as a significant problem in the treatment of 
schizophrenia (Leucht & Heres, 2006; Acosta, Hernández, Pereira, Herrera, & Rodríguez, 
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2012. Barkhof, Meijera, de Sonnevilleb, Linszena, & de Haana, 2011). Unfortunately, 
studies have shown that measuring medication adherence in patients with schizophrenia 
is difficult and no gold standard currently exists (Haddad, Brain, & Scott, 2014; Kikkert 
et al., 2008). 
Measuring medication adherence is important to both researchers and clinicians 
since estimating medication adherence inaccurately can lead to several potentially costly 
and dangerous problems (Lam & Fresco, 2015). Lam and Fresco (2015) explained that 
inaccurately measuring medication adherence can cause an effective treatment to be 
judged ineffective and expensive diagnostic procedures may be unnecessarily used. 
Currently, two methods are used in measuring medication adherence in patients with 
schizophrenia; objective and subjective methods. Subjective methods are mostly 
self-reports, informant ratings and clinician ratings and are frequently used in many 
studies (Byerly, Nakonezny, & Rush, 2008; Clayton et al., 2010; Kikkert et al., 2011; 
Ren, Herz, Qian, Smith, & Kazis, 2009; Thompson, Kulkarni, & Sergejew, 2000). 
Objective methods such as electronic monitoring, pill count, pharmacy refill records and 
plasma levels are also used in studies (Brain et al., 2014; Byerly et al., 2008; Clayton et 
al., 2010; Velligan et al., 2009). Moreover, objective measures are the recommended 
method for measuring medication adherence in this population (Velligan et al., 2009), 
however, its use is sparse in studies (Brain et al., 2014). 
Furthermore, results from both objective and subjective measures of medication 
adherence in this population are reported to be questionable. Subjective measures are 
reported to underestimate non-adherence rates (Byerly et al., 2005), while results from 
objective measures are reported to have possibly been influenced by extraneous factors 
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(Brain et al., 2014; Hiemke et al., 2011; Sacchetti & Vita, 2014; Velligan et al., 2006, 
2007, 2010; Yalcin-Siedentopf et al., 2015). Additionally, irrespective of objective 
measures being the recommended method for measuring medication adherence in this 
population (Velligan et al., 2009), varying results have been noted in studies (Velligan, 
Lam, Ereshefsky, & Miller, 2003; Velligan et al., 2007; Yang et al., 2012). 
One important element of a measurement tool is its ability to prove to be valid, 
reliable, and sensitive to change (Vitolins, Rand, Rapp, Ribisl, & Sevick, 2000). 
Additionally, these instruments need to prove to be useable and amenable to individual 
characteristics, aims and resources of the clinical setting (Lam & Fresco, 2015). These 
characteristics are essential in accurately estimating medication adherence in individuals 
with schizophrenia. The purpose of this integrative review was to assess current tools for 
measuring medication adherence in patients with schizophrenia, examining their validity 
and reliability. This review was to bring to light if any, a reliable and valid measure to 
evaluate medication adherence in this population. Additionally, this was to help improve 
strategies to enhance medication adherence in individuals with schizophrenia. 
Definitions 
Adherence 
Medication adherence can be defined as the extent to which a patient's medication-taking 
matches that agreed with the prescriber (Haddad et al., 2014). 
Non-adherence 
Nonadherence to medication includes a range of patient behaviors, from treatment refusal 





Measurement is the process of assigning numbers to objects to represent the kind 
and/or number of attributes possessed by objects (Waltz, Strickland, & Lenz, 2010). 
Medication non-adherence is measured with direct and indirect methods (Karve et al., 
2009). Direct methods include: observing patients taking medications direct observation) 
and measuring drug or metabolite concentrations in the blood or urine (Lavsa, Holzworth, 
& Ansani, 2011). Indirect methods include: asking patients, checking patient diaries, 
refill rates, pill counting, monitoring for clinical response, electronic monitoring devices, 
patient scales or surveys (Lavsa et al., 2011) and the use of administrative database 
claims (Osterberg & Blaschke, 2005). 
Abbreviations have been given to the following measures as follows: pill count 
(PC), plasma levels (PL): objective and subjective ratings (OSR), medication compliance 
(MC) and episode-specific approach (ESA). The various publications reviewed are 
discussed in sequence based on the measurement instrument identified. 
Methods 
This integrative review assesses instruments to measure medication adherence in 
patients with schizophrenia. The results from this study may help guide future clinicians 
seeking to measure medication adherence in this population. 
Inclusion and Exclusion Criteria 
The primary inclusion criterion was measurement of medication adherence in 
adult patients with schizophrenia. However, some studies that measured medication 
adherence in patients with schizophrenia also included patients with schizoaffective 
disorder, bipolar affective disorder, depression with psychotic features, schizophreniform, 
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and drug induced psychoses. These studies were also included in this review. Samples 
that included children, adolescents, geriatric patients and patients with psychiatric 
conditions other than these were excluded. 
Studies reviewed were studies conducted from 2000 to 2016, published in 
English, with a tool or method to assess or measure medication adherence in patients with 
schizophrenia that were included. Six studies met the inclusion criteria and are outlined in 
the integrative review table in the results. Various information from the articles is 
presented under the following topics: instrument and reference, description of research 
subjects, instrument description and scoring, method of measurement, validity, reliability, 
feasibility, and level of evidence. 
Databases and Search Terms Used 
In consultation with a health science reference librarian search terms were refined, 
and relevant bibliographic databases identified. The search terms used were: assessing 
medication adherence, measuring medication adherence, patients with schizophrenia, 
medication non-adherence measures and validity measures. The following databases were 
used to search for literature reporting on measures of medication adherence in 
schizophrenia: Cumulative Index to Nursing and Allied Health Literature (CINAHL), US 
National Library of Medicine PubMed service (PubMed), PsycINFO, and Scopus. 
When search terms were entered into databases, Scopus generated 46 articles, 
CINAHL generated 60 articles, PubMed nine articles and PsyInfo 157. No additional 
records were identified from other sources. A total of 272 articles were identified. After 
duplicates were removed, 210 articles remained, which were screened, and 165 records 
were excluded because they did not meet the main inclusion criteria. 
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Thirty-five full-text articles left were assessed, and 29 were excluded with reasons 
(twelve did not directly deal with measuring medication adherence, three looked at the 
efficacy of medications therapeutic monitoring), three looked at other tools other than 
medication adherence tools). One looked at errors in the measurement tools. Three 
looked at relationship between measurement tools and not specifically measuring 
medication adherence in individuals. Five articles assessed cognition, one also looked at 
side effects of medications and one addressed mental illness other than schizophrenia. 
Sampling 
A total of six studies from CINAHL, PubMed, PsycINFO and Scopus met criteria 
for inclusion. Subjects from the various articles reviewed were patients with 
schizophrenia taking various anti-psychotic medications to manage their symptoms. 
Some studies used direct measurement tools while the others used indirect measurement 
tools to assess adherence to medications in patients with schizophrenia. In all, fourteen 
instruments were identified from the articles in the review. The data obtained from the 
literature reviewed was analyzed based on the validity and reliability of the instruments 
identified for measuring medication adherence in schizophrenia. The level of evidence of 
the literature reviewed was also determined. The PRISMA 2009 diagram (Moher et al., 





Figure 1. Prisma Flow Diagram 
Results 
As discussed earlier non-adherence to medications is associated with adverse 
health conditions, especially in chronic conditions such as schizophrenia. Within the six 
studies, fourteen instruments for measuring medication adherence in schizophrenia were 
identified, and their results are presented in this section with focus on their validity, 
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reliability and sensitivity. The level of evidence of these studies was also evaluated based 
on the Center for Evidence Based Medicine Levels of Evidence (2009) appraisal format. 
Instrument Description 
Kikkert et al. (2011) measured medication adherence in patients with 
schizophrenia by using the Medication Adherence Questionnaire (MAQ), modified Drug 
Attitude Inventory (DAI), and the Compliance Rating Scale (CRS). Ren et al. (2009) 
assessed the measurement properties of three commonly used pharmacy-based measures 
(treatment persistence - TP, medication possession ratio - MPR, and medication 
compliance - MC) in addition to a new measure - episode-specific approach (ESA) to 
assess medication adherence with three typical (haloperidol, perphenazine and 
chlorpromazine) and five atypical (clozapine, olanzapine, quetiapine, risperidone and 
ziprasidone) antipsychotics. Ren et al. (2009) used a gap of ≥30 days (with no filled 
index medication) to define discontinuation of treatment as well as the number of times a 
patient returned to the same index agent after discontinuation of treatment within a 1-year 
period, which they termed medication “episodes.” 
Byerly et al. (2008) used the Brief Adherence Rating Scale (BARS), a recently 
developed instrument using the electronic monitoring (EM) tool as a reference standard 
to evaluate the BARS' reliability validity, sensitivity, and specificity. BARS took into 
consideration symptom severity in accordance with the 30-item Positive and Negative 
Syndrome Scale (PANSS) measure. 
Brain et al. (2014) used the Medication Event Monitoring System (MEMS®), Pill 
Count, Plasma Levels and Subjective and Objective Rating Scale (patient, staff, 
psychiatrist and close informant ratings) to measure medication adherence in patients 
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with schizophrenia. They measured the validity of their instruments using the Pearson's 
χ2 -method or Fisher's exact test and used kappa (“Κ”) coefficients to describe the 
agreement between MEMS® and the other measures. Inter-rater reliability for the plasma 
level was also assessed in the study. Brain et al. (2014) compared relationships between 
MEMS® adherence and each of the other measures. They also measured inter-rater 
reliability for the plasma level. Additionally, they analyzed the interrelationships between 
all measurements using a principal component analysis, with Oblimin rotation. 
Thompson et al. (2000) used the Medication Adherence Questionnaire (MAQ) a 
four-item questionnaire related to medication-taking behaviors of patients; Drug Attitude 
Inventory (DAI), the most commonly used self-report measure of compliance that 
includes a 30-item questionnaire - measuring subjective positive attitudes, subjective 
negative attitudes, health/illness, physician, control, prevention, and harm; and the 
Medication Adherence Rating Scale (MARS) developed from the DAI and MAQ by 
applying item response theory (IRT). They tested for reliability with Cronbach's alpha 
(internal consistency) and test–retest. Parallel-forms chi-square tested for goodness of fit, 
the construct validity in the MARS was validated using a multitrait–multimethod matrix, 
carers' estimate of subject compliance, and blood test results. 
Finally, Clayton et al. (2010) measured the degree of adherence among patients 
prescribed antipsychotic medications from existing pharmacy claims data from Medicaid 
programs in Missouri, Alaska, and Utah for two 12-month periods (January 2006 to 
December 2006 for Missouri and July 2006 to June 2007 for Alaska and Utah). They first 
used a clinician-rated structured instrument to assess patients' medication adherence and 
then used a 12-item scale, the Medication Adherence Assessment Tool (MAAT) 
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developed by a group of experts using a consensus methodology after review of the 
adherence literature, as part of a project sponsored by Ortho-McNeil Janssen Scientific 
Affairs, LLC. They then compared MAAT results with results from indirect measures of 
treatment adherence derived from pharmacy data, the medication possession ratio (MPR), 
which they indicated as an already validated tool. Cronbach's alpha was used to check 
validity of these instruments. 
Reliability and Validity of Subjective Measures 
Medication Adherence Questionnaire (MAQ) 
This instrument was used by both Kikkert et al. (2011) and Thompson et al. 
(2000). Kikkert et al. (2011) revealed that the MAQ items were directly related to 
medication intake behavior among the patients and found sensitivity and specificity for 
time to relapse and admission. At 95% confidence interval using upper and lower 
boundaries, respectively, logistic regression on the MAQ showed prediction for relapse 
between 0.345–0.852 and 0.299–0.874 for admission. Furthermore, at 95% confidence 
interval using lower and upper limits respectively on Cox Regression to predict time to 
relapse and admission, the MAQ showed time to relapse between 0.537 and 0.874 and 
0.443 and 0.950 for time to admission. When checking for relapse, the MAQ had 63.6 
sensitivity and 59.7 specificity and for admission, the MAQ had 87.5 sensitivity and 54.5 
specificity. The MAQ was both predictive for relapse and for time to relapse. Kikkert et 
al. (2011) concluded that, 42% of patients who the MAQ rated non-adherent to 




In Thompson et al. (2000), the MAQ had a reliability of 0.76 Cronbach's alpha. 
When test–retest reliability was assessed after a 2-week interval using the parallel-forms 
chi-square, it had a goodness of fit of 0.76. When they assessed the internal validity of 
the MAQ using IRT, the MAQ showed good internal validity but no data or analysis was 
offered to support this claim. When construct validity of the MAQ was analyzed using a 
multitrait–multimethod matrix, there was a positive correlation with blood results. See 
table below for more details. 
Medication Adherence Rating Scale (MARS) 
Thompson et al. (2000) analyzed the MARS for reliability using Cronbach's 
alpha, which was 0.75. The test–retest reliability assessed after a 2-week interval using 
the parallel-forms chi-square to test the goodness of fit was 0.72 for the MARS. 
Thompson et al. (2000) brought to light that, after the internal validity of the MARS was 
assessed by using IRT, results suggested that it had good internal validity because all the 
items fit the model. Thompson et al. (2000) stated that the MARS had a high level of 
validity and appeared to account for the complexity of compliance behavior. They further 
stated that the MARS was believed to have a greater utility in a number of settings 
because it is more time and cost-effective than many methods of measuring compliance. 
They also indicated that the MARS had good convergent or construct validity. Moreover, 
it appears to be a reliable and valid tool for estimating compliance, with greater validity 
than the other measures they used in their study. 
Objective and Subjective Ratings (OSR) 
Regarding OSR, Brain et al. (2014) used a 5-point scale (1 = “0–20%”, 2 = “21–
40%”, 3 = “41–60%”, 4 = “61–80%”, and 5 = “81–100%”) to measure adherence. For the 
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dichotomous adherence variable, category 5 was considered adherent. Results indicated 
that among the subjective measurements, the highest figure was observed for the self-
rated measure (mean adherence 92%) by patients or informants, and the lowest for the 
clinical staff and prescribing psychiatrists (58%). 
Drug Attitude Inventory (DAI) 
Kikkert et al. (2011) used the DAI to assess for adherence in schizophrenia. They 
explained that, the DAI focused on a patient's attitudes toward medication (medication 
intake behavior). When logistic regression was used at 95% confidence interval using 
both upper and lower limits, respectively, to predict for relapse and admission, the results 
showed between 0.721 and 1.091 for relapse and 0.572 and 0.976 for admission DAI. 
When Cox Regression was used at 95% confidence interval (lower and upper levels, 
respectively), the results showed between 0.798 and 1.034 for prediction time to relapse 
and 0.642 and 0.987 for admission DAI. The DAI showed 18.2 for sensitivity and 90.0 
specificity for relapse and for admission it showed 20.0 for sensitivity and 87.0 for 
specificity. 
Thompson et al. (2000), revealed that, the DAI had a reliability of 0.77. They also 
had the test–retest reliability assessed after a 2-week interval using the parallel-forms chi-
square, and the DAI had a goodness of fit of 0.60. They concluded that the DAI appeared 
to have poor internal validity, which may be due to the fact that it may have assessed 
more than one underlying construct. 
Compliance Rating Scale (CRS) 
Kikkert et al. (2011) measured adherence with the CRS for prediction of relapse 
and admission with logistic regression. At a 95% confidence interval, the CRS showed 
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0.505–0.995 prediction for relapse and 0.277–0.822 for admission. With Cox regression 
at 95% confidence interval for both lower and upper levels used to predict time to relapse 
and admission, CRS showed 0.659 (upper) and 0.980 (lower) for relapse and 0.469 
(lower) and 0.845 (upper) prediction for admission. Kikkert et al. (2011) further found 
that CRS showed 34.0 sensitivity and 90.3 specificity for relapse. Kikkert et al. (2011) 
also found that, for admission, the CRS had 38.5 sensitivity and 81.8 specificity. Kikkert 
et al. (2011) concluded that the CRS was predictive for time to hospital admission, but 
the clinical relevance of these effects was, however, limited. 
Treatment Persistence (TP) 
Ren et al. (2009) used treatment persistence (TP) which defines medication 
discontinuation based on gap between administrations of ≥30 days. Their results revealed 
that among the atypical agents, patients who initiated on clozapine were most adherent, 
whereas patients who were initiated on risperidone were least adherent. Patients on the 
typical agents who initiated on perphenazine were most adherent and those initiated on 
haloperidol were least adherent. The results also indicated that initiators of olanzapine 
and ziprasidone stayed on treatment for the same duration (151 days). 
Furthermore, patients who initiated chlorpromazine were reported to have 
remained on medication treatment slightly longer than initiators of haloperidol (117 vs 
110 days, p < 0.05). Ren et al. (2009) further stated that TP uses only the first medication 
episode, which combined the single prescription for patients who had one prescription 
with the first episodes among patients who had two or three medication episodes. Ren et 
al. (2009) indicated that results from TP are problematic because it excludes the second 
episode among patients with two medication episodes and the second and last episodes 
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among those with three medication episodes. Ren et al. (2009) therefore concluded that 
results based on the TP approach are likely to be biased. 
Medication Possession Ratio (MPR) 
Ren et al. (2009) used a gap of ≥30 days to define discontinuation of medication 
treatment and took into account all medication episodes with the MPR. The study 
revealed that most patients on atypical agents who initiated clozapine were rated 
adherent, whereas patients who initiated risperidone were least adherent. With the typical 
agents, most patients who initiated perphenazine were rated adherent while those initiated 
on haloperidol were least adherent. However, Ren et al. (2009), stated that initiators of 
ziprasidone stayed on treatment significantly longer than initiators of olanzapine (269 vs 
246 days; p < 0.001), and those initiated on ziprasidone remained on treatment slightly 
longer than initiators of quetiapine (269 vs 266 days are however not statistically 
significant). Initiators of chlorpromazine remained on medication treatment significantly 
longer than initiators of haloperidol (234 vs 197 days, p < 0.001). 
Clayton et al. (2010) revealed that the MPR identified 20% of patients in the 
sample (58 out of 289) non-adherent to their antipsychotic medications using the 
threshold of 0.8 for adherence. Looking at these two studies, MPR rated most of the 
participants in Ren et al. (2009) adherent, but Clayton et al. (2010) found that most of 
these participants rated non-adherent. 
Ren et al. (2009) stated that the MPR lumps together patients with different 
numbers of medication episodes; hence one would not be able to capture the differences 
in medication adherence between patients with one medication episode and those with 
multiple medication episodes. They further indicated that because MPR does not consider 
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the size of the gap in defining discontinuation of medication treatment, using MPR as a 
measure for adherence is problematic. 
Medication Compliance (MC) 
Ren et al. (2009) considered the size of the gap (i.e., ≥30 days) to define 
discontinuation of medication treatment as indicated on the MC measure. The study 
revealed that initiators of quetiapine remained on treatment significantly longer than 
initiators of ziprasidone (191 vs 178 days; p < 0.05). Ren et al. (2009) went on to say 
that, although MC considers all medication episodes, it also lumps together patients with 
different numbers of medication episodes and one would not be able to capture the 
differences in medication adherence between patients with one medication episode and 
those with multiple medication episodes. 
Medication Adherence Assessment Tool (MAAT) 
According to Clayton et al. (2010), the ability of the MAAT total score to predict 
adherence as objectively measured by MPR was analyzed using simple linear regression. 
There was statistical significance with a little less than 5% variability in MPR, which was 
explained by a patient's total MAAT score. They further state that internal consistency of 
the MAAT was excellent on Cronbach's [alpha] scores, and inter-rater reliability was 
excellent (r = 0.994 for the total score; with inter-rater reliability on individual items 
ranging from 0.608 to 1.0). Clayton et al. (2010) shared a concern that, despite these 
statistically significant findings, clinicians were unable to reliably detect nonadherence 
among their patients who were prescribed antipsychotic medications using the MAAT 




Episode-Specific Approach (ESA) 
Ren et al. (2009), developed a new measure, the ESA, which stratifies the number 
of medication episodes and compares medication adherence across antipsychotic agents. 
Findings revealed that the number of days remaining on medication treatment across 
different antipsychotics tended to vary across different medication episodes. Among the 
three typical agents, initiators of chlorpromazine had better medication adherence than 
initiators of haloperidol, but the differences were non-significant among those with one 
medication episode (131 vs 124 days). Among those with two medication episodes, the 
difference was moderate (191 vs 171 days; p < 0.05). However, among those with three 
or more medication episodes the difference was strong (195 vs 154 days; p < 0.001). 
With the five atypical agents, ESA on one hand rated initiators of olanzapine to 
have stayed significantly longer on treatment than initiators of risperidone when on three 
or more medication episodes (199 vs 192 days, p < 0.01); however, the difference 
between these two agents was non-significant if the patient was on a first (171 vs 168 
days) or second medication episode (198 vs 199 days). On the other hand, ESA rated that 
initiators of quetiapine and ziprasidone were poorly adherent when on a single 
medication episode (172 vs 186 days; p < 0.001), but more adherent when on a second 
medication episode (222 vs 210 days; p < 0.01). 
Brief Adherence Rating Scale (BARS) 
Byerly et al. (2008) assessed a recently developed tool (BARS) for reliability, 
validity, sensitivity, and specificity by using the electronic monitoring (EM) tool as a 
reference standard every six month and the PANSS score for symptom severity. Their 
results indicated high internal reliability for the BARS across the six-monthly assessment 
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periods (α = 0.92) and a moderate-to-strong linear relationship between initial monthly 
BARS adherence and subsequent BARS adherence. For the various initial BARS 
assessment periods in relation to subsequent BARS adherence, robust regression 
coefficients ranged from 0.53 to 0.92, and Spearman's correlations (rs) ranged from 0.46 
to 0.86. With a mean of ≥71%, the BARS showed adherence among 52.5% (n = 32) of 
the participants, while 47.5% <71%, (n = 29) were non-adherent. There was a significant 
inverse relationship with concurrent validity and correlation between BARS adherence 
and PANSS (β = −0.08, p = .007; rs = −0.28, p = .02) as lower adherence was associated 
with more severe positive symptoms. 
Byerly et al. (2008) also reported a significant inverse relationship between BARS 
adherence and PANSS (β = −0.09, p = .02) on the robust regression analysis with no 
statistical significance in relationship with the Spearman rs (rs = −0.23, p = .07) but 
rather a significant inverse relationship (β = −0.40, p < .0001; rs = −0.39, p = .002). An 
initial 3-month BARS assessment period with a cutoff of <74% mean adherence (mean of 
months 0, 1, and 2) had sensitivity of 73.1% and specificity 74.3% in detecting non-
adherence. BARS detected 54.1% (n = 33) of the participants adherent, and 45.9% (n = 
28) non-adherent. At a cutoff of <71% mean BARS adherence rating for the 6 monthly 
BARS assessments, 52.5% (n = 32) were adherent, and 47.5% (n = 29) non-adherent with 




Reliability and Validity of Objective Measures 
Pill Count (PC) 
Brain et al. (2014) found that mean adherence as measured by pill count was 82% 
(95% C.I. 77–87%) across the study period, with a non-significant drop from 86% at 
baseline to 81% during the last two-month period [F (1, 116) =2.25, p = 0.137]. 
Plasma Levels (PL) 
Brain et al. (2014) found that the samples collected from patients varied. Three 
blood samples were collected from 51 patients, two samples from 32 patients, and one 
sample from 15 patients. Results indicated that more than half (56%) of the patients were 
adherent according to plasma-based measurement. Brain et al. (2014) brought to light that 
the inter-rater reliability for the plasma level adherence measure was very high (Κ = 0.92, 
p < 0.001). 
Medication Event Monitoring System (MEMS®) 
Brain et al. (2014) revealed that the mean adherence for MEMS® across the study 
period was 84% (95% C.I. 73–88%). Results indicated that MEMS® adherence changed 
from 85% at baseline to 82% for the final two-month period. This change was, however, 
not statistically significant [F (1, 116) <1.00, p = 0.475]. Forty-four percent of the 
patients were differently classified; 31 (32%) were classified as adherent according to 
MEMS®, and 11 (12%) non-adherent. Similar to MEMS is the electronic monitoring 
(EM) used in Byerly et al. (2008), which rated participants as adherent from a ≥ 70% 
mean adherence for a six-month period. The EM rated 57.4% (n = 35) of the participants 
and the remaining 42.6% of the participants (n = 26) with <70% non-adherent. 
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Results from the studies reviewed on validity and reliability of measures are summarized 
on the Table 1 below. 
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Table 1: Validity and Reliability of Measures  
Author/Adherence Measure  Reliability of measure Validity of measure Interpretation 
Byerly et al. (2008) 
BARS  
 
Inter-rater reliability Cronbach's 
coefficient alpha across six monthly 
assessment periods (α = .92). 
Robust regression coefficients ranged 
from 0.53 to 0.92 
Spearman's correlations (rs) ranged from 
0.46 to 0.86 
Concurrent validity assessed with 
relationship between BARS adherence and 
PANSS  
Simple linear robust regression and 
Spearman rs respectively  
• BARS adherence and PANSS 
total score (β = − 0.40, p < .0001; 
rs = − 0.39, p = .002). 
• BARS and Positive symptom sub-
scale score β = − 0.08, p = .007; 
rs = − 0.28, p = .02 
• BARS adherence and Negative 
symptom sub-scale score with the 
robust regression analysis (β = − 
0.09, p = .02), Spearman rs (rs = 
− 0.23, p = .07) 
Cronbach alpha revealed very high 
internal reliability for the BARS 
across the 6 monthly assessment 
periods (α = .92) 
Spearman's rs, revealed a 
moderate-to-strong linear 
relationship between initial 
monthly BARS adherence and 
subsequent BARS adherence. 
BARS adherence and PANSS total 
score revealed a significant inverse 
relationship. lower adherence was 
associated with more severe 
positive symptoms 
Brain, et al. 
(2014) 
MEMS 
Pill count (PC) 





Pearson's χ2 –method/ Fisher's exact 
test.  
MEMS relationship with other measures 
Results not clearly stated for all 
adherence measures 
 
Kappa (“Κ”) coefficients 
MEMS, K coefficient was 0.72 (p<0.001) 
MEMS correlation with other  
measures as follows; 
Pill count =0.72  
Plasma Level =0.05 (p=0.607) 
Patient =0.30  
Informant = 0.46 
Staff = 0.30 
Psychiatrist=0.31 
MEMS highly correlated with pill 
count with p<0.001 with very low 
relationship with plasma levels 
(p=0.607). 
MEMS K coefficient was reported 




Author/Adherence Measure  Reliability of measure Validity of measure Interpretation 





Internal consistency  
(Cronbach's alpha), and  
parallel-forms Chi-square 
for goodness of fit test–retest  
reliability respectively  
MARS = 0.75, 0.72  
MAQ = 0.76, 0.76  
DAI. = 0.77, 0.60  
Multitrait–multimethod matrix for 
construct validity with other measures. 
Quest for Internal validity internal validity 
using IRT  
(**p<0.01, *p<0.05) 
DAI and MAQ = 0.40  
DAI and MARS = 0.82  
DAI and Carer rating= 0.29 
DAI and Bloods Level= 0.65  
MAQ and MARS  = 0.79 
MAQ and Carer rating = −0.32 
MAQ and Bloods Level = 0.36 
MARS and Carer rating = −0.03 
MARS and Bloods Level = 0.60  
Carer rating and Bloods Level = 0.57 
MARS was significantly correlated 
with other self-report measures of 
compliance. Higher correlation 
was between the MAQ and the 
MARS than between the DAI and 
MARS. No relationship between 
carers' rating and MARS score. 
Stronger positive correlation was 
seen with blood results than the 
MAQ and a slightly lower 
correlation than the DAI. Supports 
a good convergent or construct 
validity for the MARS. MARS and 
MAQ, had good internal validity. 
However, DAI had a poor internal 
validity. 




No instrument indicated to measure 
reliability 
Cox Regression model was used to 
measure validity for relapse and 
admission. 
At level of evidence set at 
and 95% confidence interval 
respectively.  
MAQ was reported significant 
predictor for relapse with DAI 
been poor predictor. 
 
  For prediction for relapse 
MAQ = 0.008 and 0.345-0.852.  
DAI = 0.255 and 0.721–1.091.  CRS = 




Author/Adherence Measure  Reliability of measure Validity of measure Interpretation 
  For prediction for admission  
MAQ = 0.014 and 0.299–0.874 
DAI = 0.032 and 0.572–0.976 
CRS = 0.008 and 0.277–0.822 
CRS was reported significant for 
admission while DAI was poor 
predictor. 
Clayton et al. (2010) 
MAAT 
MPR 
MAAT = r0.994 for the total score.   
MPR = r2 (0.0496) 
with inter-rater reliability on individual 
items ranging from 0.608 to 1.0) 
 
Content validity; stepwise  
fashion using Cronbach's  
[alpha]. Convergent validity assessed by 
simple linear regression 
Spearman and Pearson correlation. 
Statistical significance set at P<0.05, 2-
tailed.  
Cronbach's [alpha] scores showed.  
For regression coefficient MAAT = 
(P<0.001)  
MPR = (P<0.0073) 
 
MAAT reported excellent Inter-
rater reliability (r=0.994 for the 
total score; with inter-rater 
reliability on individual items 
ranging from 0.608 to 1.0) 
MAAT was reported to be 
internally valid and significantly 
predicted adherence. 
<5% variability in MPR was 
explained by a patient's total 
MAAT 






Did not look at reliability of measures 
used 
Did not look at validity of measures used High reliability reported for ESA 
Reliability reported for patients on 
multiple medications for MC 
Reliability reported for patients on 





Comparison of Instruments 
Measuring medication adherence is truly difficult when it comes to schizophrenia. 
Comparing results from various instruments for measuring medication adherence in 
schizophrenia showed varied results; there is no gold standard. Both the DAI and CRS 
had high specificity and labeled most patients adherent (86% and 79% respectively); 
however, both had low sensitivity, with the DAI having the worst predictive validity 
(Kikkert et al., 2011). Moreover, the DAI appeared to have poor internal validity, likely 
assessing more than one underlying construct (Thompson et al., 2000). The MAQ was 
said to be the least problematic predictor for relapse and time to relapse; it had high 
sensitivity and specificity, with the best sensitivity of all instruments for relapse. It was 
moderately predictive for admission (Kikkert et al., 2011). There was a strong positive 
correlation observed between the results of the DAI and MAQ, and a positive relationship 
(0.60) was observed when correlated with blood levels of lithium and Tegretol. This 
result was also affirmed by Thompson et al. (2000). 
Comparing measures that looked at patients on antipsychotic medications, ratings 
for medications by these measures were mixed. Both the MPR and the TP rated patients 
on atypical agents, with those initiated on clozapine most adherent and those initiated on 
risperidone least adherent (Ren et al., 2009). For typical agents, initiators of perphenazine 
were most adherent and those initiated on haloperidol least adherent. However, with 
initiators of ziprasidone, MPR rated them remaining on treatment slightly longer than 
initiators of quetiapine (269 vs 266 days); this difference was statistically non-significant. 
This insignificance was similar when comparing quetiapine and olanzapine (269 vs 246 
days; p < 0.001) (Ren et al., 2009). MC revealed that initiators of quetiapine remained on 
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treatment significantly longer than initiators of ziprasidone (191 vs 178 days; p < 0.05) 
while TP rated initiators of olanzapine and initiators of ziprasidone staying on treatment 
for the same duration (151 days). Additionally, both MPR and TP rated initiators of 
chlorpromazine remained on medication treatment significantly longer than initiators of 
haloperidol (234 vs 197 days, p < 0.001 and 117 vs 110 days, p < 0.05 respectively) (Ren 
et al., 2009). 
The MEMS® adherence showed a high correlation with the pill count 
measurement; although differently classified, different numbers of patients were 
classified as adherent by the two measures (Brain et al., 2014). The relationship between 
MEMS® and plasma levels was very low, as plasma levels classified most patients as 
non-adherent, unlike the MEMS®. These results are said not to be independent, as high 
loadings (>0.50) were also found between patient and staff ratings, and between MEMS® 
adherence and pill count (Brain et al., 2014). 
When EM and BARS were compared, mixed model repeated measures analysis 
revealed no significant instrument effect (EM vs. BARS; F = 0.25, df = 1, 92.1, p = .61) 
and no significant instrument × period interaction (F = 1.61, df = 5, 317, p = 0.16) 
(Byerly et al., 2008). Further, the test of simple instrument effects (in each period) 
showed no significant instrument differences on adherence in any of the six prospective 
months (F's < 1.16, p's > 0.28). However, there was a significant positive relationship 
between BARS adherence and EM adherence across the average of the six-monthly 
assessments (β = 0.98, rs = 0.59, p < .0001). BARS could identify patients' oral 
antipsychotic medication non-adherence vis-à-vis EM adherence in an initial three-month 
adherence assessment period (Byerly et al., 2008). 
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Comparing MAQ, DAI, and MARS, the MARS was significantly (p = −0.03) 
correlated with other self-report measures of compliance (observer rating), although the 
correlation was higher between the MAQ and the MARS than between the DAI and 
MARS (Thompson et al., 2000). The MARS had good internal validity according to IRT 
analyses, and after discarding inconsistent items, it produced even greater internal 
validity and reliability. Analysis of the MARS using Cronbach's alpha was 0.75, 
compared to 0.76 for the MAQ, and 0.77 for the DAI. MARS had good convergent or 
construct validity as well as internal validity (Thompson et al., 2000). 
When the MAAT was compared with the MPR, the MAAT had good internal 
reliability, but the scores were not significantly (p = 0.0073) correlated with MPR and 
performed poorly when compared to the MPR (Clayton et al., 2010). Almost half the 
variability in MAAT score is explained by the clinician's belief about whether the patient 
was adherent when the relationship between total MAAT score and the clinician's simple 
assessment of adherence was compared (Clayton et al., 2010). Additional methodological 
details about these studies is in Table 2 below (instrument/reference, type of study, 
description of research subjects, instrument description, method of measurement and 
scoring, validity, reliability, feasibility, and level of evidence).
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Subjective measures such as the OSR, MAQ, DAI, and MAAT, although 
convenient to both patient and informants, stand a greater chance of being biased. All the 
measures that were subjective showed higher ratings of self-ratings (the patient rating) 
and mixed results for informant ratings (clinicians and family/friend). Many factors can 
cause these biases. Subjective assessments are likely to be inaccurate and tend to 
overestimate levels of adherence (Velligan et al., 2010). For example, most patients are 
likely to rate themselves as adherent and would not want clinicians to think that they do 
not take their medications. Another bias is by informants, such as family, who may rate 
patient’s adherent where clinicians may rate them as non-adherent. There have also been 
reports of physician frequently underestimating the degree of nonadherence of their 
patients (Sacchetti & Vita, 2014). Results analyzed indicate that neither physician report 
nor patient self-report accurately identified adherence when compared with data from 
electronic monitoring or pill counts (Velligan et al., 2007). 
Another issue is that, two or more clinicians may not rate independently, and 
rating may be based on previous knowledge of patients' medication taking behavior. A 
typical example is the MAAT scores about which Clayton et al. (2010) observed good 
internal reliability, yet clinicians were unable to reliably detect nonadherence among their 
patients who were prescribed antipsychotics because results were highly correlated with 
the physician's belief about whether the patient was adherent, not with the objective 
measure of adherence. Additionally, data from health management organizations, or 





since filling a prescription by no means insures that the medication was ingested, and it is 
important to look at prescription refills over time (Kane, Kishimoto, & Correll, 2013). 
This makes objective and subjective measures' validity and reliability 
questionable. Objective measures such as the MEMS®, EM and PC, seem to be an easy 
way to measure adherence but unreliable as they are not able to actually measure pill 
discarding and whether or not all pills were actually ingested by the patient. Patients may 
take more than one dose out of the bottle at a time, not take any pills out at all, or fail to 
replace the cap, or may fill prescriptions in locations where there is no record, resulting in 
missing data (Velligan et al., 2010). Another issue is that it is easy for a patient to discard 
some pills or transfer them to another bottle (Kane et al., 2013). Samples or old 
medications are also noted to compromise the results obtained using pill counts and 
pharmacy refill records (Velligan et al., 2010). These electronic monitoring devices; 
MEMS pill bottle caps, although common, are costly (Davies et al., 2010). 
Plasma level (PL) instruments used to measure medication adherence may be 
questionable and not a reliable measure. It is very possible that false negative (medication 
not in blood) or positive (adequate medication in blood) results will be obtained from 
blood samples. For example, individual variations, such as fast or poor metabolisms 
(Yalcin-Siedentopf et al., 2015), can cause an individual to be falsely rated adherent or 
non-adherent. Additionally, patients knowing they are in a research study may take 
loading doses prior to laboratory blood sample draws and may wrongly be rated adherent. 
Similarly, misinterpretation in laboratory values, increases in dosage of medications, 
switching, and even the prescription of additional medications could affect these results 





attributed to age, concurrent diseases, concomitant medication, genetics, lifestyle 
activities (i.e. smoking and caffeine use) and can affect plasma levels of medications 
(Hiemke et al., 2011; Velligan et al., 2007). 
For these reasons, it is very important to interpret results from PL with caution 
(Yalcin-Siedentopf et al., 2015). Furthermore, blood sample collection represents a 
snapshot in time (Mattson, 1995), meaning the results might not be a true reflection of 
adherence behavior of a patient. Another issue with PL as a measure is that patient refusal 
to do blood draws could be rated as non-adherent but it may be avoidance of the pain of 
needle. All these factors do not make the PL measure reliable or a valid measure. This 
suggests that PL is not a very reliable way of measuring adherence. These objective 
measures are said to be associated with significant errors (Velligan et al., 2006). 
Treatment persistence (TP), medication possession ratio (MPR), medication 
compliance (MC), and the episode-specific approach (ESA) were used to assess 
medication adherence with the typical and atypical antipsychotics. Results varied, and no 
two instruments gave the same ratings for all medications across the study period. Apart 
from the ESA, all the others did not consider the uniqueness of each patient to rate their 
medication adherence behaviors; some considered only one medication. Those that 
considered two or more medications ended up lumping together patients with different 
numbers of medications. In the treatment of schizophrenia, there can be a lot of 
medication switching and multiple medication prescription, especially in complicated 
(Ren et al., 2009) and acute cases. It is always important to consider the acuity of the 
patient's symptoms since stable patients are more likely to adhere to medications than 





non-adherent unfairly; due to this fact, these measures are not reliable for all cases of 
schizophrenia. 
ESA accounted for the medication episodes, level of patient's recovery and 
number of days remaining on the medication treatment. It therefore provides a fair 
comparison of medication adherence across antipsychotic agents by avoiding potential 
bias against those patients on multiple medication episodes (Ren et al., 2009). This 
approach seems promising although the instrument has not been thoroughly analyzed. 
Another important finding from this review is that some studies (Brain et al., 2014) 
reported conducting the study on patients who were high functioning and might already 
be adherent to their medications; this makes results from such studies not generalizable. 
Futures studies should ensure generalizable representations of the population to ensure 
true comparisons of adherence measures. 
It is of importance to consider the following factors when measuring adherence to 
medication in schizophrenia: the number of medications the patient is taking, the level of 
the patient's recovery (symptom severity), and the number of days of a patient's 
treatment. Patients with schizophrenia take different medications for different reasons, 
and the prescribed medication may change due to switches among antipsychotic agents 
and adherence behaviors (Ren et al., 2009). Recognizing the number of medications, a 
patient is on and determining the type of measure to use is very important but attempts by 
current measures to do this have proven futile. 
At least three limitations were noted to be associated with this review. Some 
studies gave values for significant results obtained from the measures used and others did 





others did not. Furthermore, the length of study periods varied widely among the studies 
reviewed. This made it somewhat difficult to compare results of the instrument from 
various studies to make conclusions. However, irrespective of these limitations, the 
findings of this review were not affected. 
This review found that, based on the ratings of the Oxford Centre for Evidence-
based Medicine Levels of Evidence (2009), there were wide variations in the levels of 
evidence of the reviewed instruments. MEMS®, PC, and OSR have level one-a evidence, 
because they were used across different populations. The MARS has a level three-b 
evidence since it has been used on limited populations, and further generalization is 
needed. BARS and ESA are supported by one-b and three-b levels of evidence since they 
have been validated across single and limited populations. Both need further studies for 
generalizability. The remaining measures (MAQ, DAI, CRS, TP, MPR and MC) are 
supported by level four evidence since they lack sensitivity. Also, PL has a level of 
evidence of five because it is based on physiological results. 
Clearly, the conventional approaches to measure medication adherence among 
those with schizophrenia are inadequate. Subjective methods like self-reports and 
physician reports are most commonly used in measuring adherence (Velligan et al., 
2009), but they have issues with validity and reliability. On the other hand, objective 
instruments such as electronic medication monitoring, pill count or pharmacy-based 
measures, may enhance the chance of detecting adherence problems (Kikkert et al., 
2011), but may not reflect the dosage actually ingested by the patient (Yalcin-Siedentopf 





In this review, only three instruments had some validity, reliability and 
sensitivity: the ESA, the BARS and the MARS. However, these recently developed 
instruments need greater generalizability in order to yield better validity and reliability in 
measuring medication adherence in this population. 
In conclusion, these findings highlight a challenge to researchers to develop an 
adherence instrument that takes into account the number of medications the patient is 
taking, the level of the patient's recovery, and the number of days of a patient's treatment 
for the instrument to yield validity, reliability and sensitivity with a better level of 
evidence. 
Conclusion 
Measuring medication adherence in patients with schizophrenia is important as 
medication non-adherence rates in this population continue to be alarmingly high, and 
therefore of public health concern. Results from assessing current instruments 
demonstrate that additional evidence is needed to measure medication adherence in 
patients with schizophrenia; no gold standard currently exists. Existing conventional 
instruments, in addition to having inadequate validity and reliability, did not consider 
patients' special characteristics and had low levels of evidence due to a lack of 
generalizability. Two recently developed instruments (MAR and ESA) formulated by 
modifying some existing conventional instruments and the BARS seem promising, as 
they had better validity and demonstrated adequate sensitivity to the unique 
characteristics of patients. These new instruments, however, require generalizability and 





In conclusion, this integrative review validates that better instruments to measure 
medication adherence in patients with schizophrenia are needed because current 
instruments either lack sensitivity, well established validity or generalizability. When 
researchers respond to this urgent call to formulate an instrument that has validity, 
reliability and sensitivity in measuring medication adherence in patients with 
schizophrenia, clinicians will be better able to address issues of non-adherence to 
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BACKGROUND: Poor medication adherence is a significant problem in individuals with 
severe mental illness (SMI). About 50% of people with SMI become nonadherent to 
treatment in the first month following discharge from the hospital.  
 
OBJECTIVE: This study examined literature in the past decade (2006-2016) on the use 
of mobile phone contacts in individuals with SMI to improve medication adherence post 
hospital discharge.  
 
DESIGN: This integrative review used the search terms texting, text messaging, SMS, 
cell/mobile phone, medication adherence, medication compliance, and mental illness. 
Databases (CINAHL, PubMed, PsycINFO, and Scopus) and manual searching of 
reference lists were done. The main inclusion criteria were the use of mobile phone 
contacts on medication adherence in individuals with SMI. Adults 18 years and older, 
studies conducted from 2006 to 2016, and studies conducted in English were also criteria 
for inclusion. Only five studies met criteria for inclusion.  
 
RESULTS: Outcomes from the review showed that mobile phone contacts have been 
used to improve medication adherence in individuals with SMI and able to provide the 
four types of social support (instrumental, informational, emotional, and, appraisal). 
When phone contacts especially text messaging was used as an adjunct to other 
interventions, it yielded better medication adherence than when used alone. However, 
results on medication adherence rates were mixed in participants on both psychiatric and 
non-psychiatric medications.  
 
CONCLUSION: Although mobile phone contacts are a promising tool to enhance 
medication adherence after hospital discharge, its effectiveness to increase medication 







Poor medication adherence is a significant problem in individuals with severe 
mental illness (SMI). Medication nonadherence has been linked to more rapid disease 
progression, increased disease complications, poorer functional outcomes, lower quality 
of life (Najt, Fusar-Poli, & Brambilla, 2011; Novick et al., 2010), increased violent 
behavior (Van Dorn, Volavka, & Johnson, 2012), increased suicide attempts (Novick et 
al., 2010), and earlier/more frequent rehospitalization (Brown, Bennett, Li, & Bellack, 
2011; Najt et al., 2011). Studies have shown that in the first month following discharge 
from the hospital, about 50% of individuals with SMI become nonadherent in managing 
their treatment, a major factor influencing acute psychiatric hospital readmission (Tomko 
et al., 2013). Increased nonadherence to prescribed medications after discharge has been 
linked to failure of follow-up care after discharge, resulting in failure to achieve the full 
benefits of treatment (Lee et al., 2015) and higher mental health care cost (Pantalon, 
Murphy, Barry, Lavery, & Swanson, 2014; American Pharmacist Association 2013). 
When patients are due for discharge, providers, caregivers and patients may 
perceive that they can take care of themselves, but they need support despite apparent 
recovery (Bickley et al., 2013). All patients may require some support; however, support 
is essential for individuals with SMI. In all individuals, the core network for support 
(friends and family members) closest to the individual (Perry, 2011) is most likely to 
provide emotional, social, and economic support through communicating, controlling 
emotions and behaviors, problem solving, and positive coping behaviors (Sawant & 
Jethwani, 2010). However, mental health problems can cause changes in this network’s 





al., 2002) sometimes irreversibly. This lack of support from a core social network can 
cause challenges for individuals with SMI, especially after hospital discharge when they 
are faced with barriers such as lack of transportation, difficulties in making medical 
decisions, managing personal health problems, and troubling mental health symptoms 
(Nath, Wong, Marcus, & Solomon, 2012). 
Additionally, other social connections such as coworkers, neighbors, 
acquaintances, extended kin, and friendships with limited contact may be peripheral with 
weak and unstable ties (Perry, 2011). Many of these peripheral network relationships 
become strained because symptoms associated with SMI can provoke fear and discomfort 
(Perry, 2011). A strain in both core network and peripheral ties can therefore lead to a 
lack of social support for these individuals. For example, one study found that individuals 
who seek mental health support begin treatment with larger and more broadly functioning 
social networks, but the size of their social network decreases over time (Perry & 
Pescosolido, 2015). 
An additional important source of support for individuals with SMI are mental 
health practitioners who provide greater support to patients at both admission and 
discharge. Since mental health practitioners are highly involved with individuals with 
SMI, assisting them to identify sources of support, build social skills, develop 
friendships, discover new programs, and find community services, they may be a strong 
source of social support for these individuals (Sirin et al., 2013), even after hospital 
discharge. Identifying a person whom the patient perceives provides them with social 
support (Sawant & Jethwani, 2010) is necessary for continuity of care and recovery from 





individuals with SMI, there is a need to make this process less cumbersome to both the 
health care practitioner and the individuals with SMI, to ensure that adequate social 
support, encouragement, and treatment (Sawant & Jethwani, 2010) are provided. 
One method that health care professionals have used to provide support to 
individuals with SMI to improve medication adherence post discharge is the use of 
technology. Technology has shown to increase patients’ levels of perceived control, 
autonomy, self-esteem, participation in social activities (Palmier-Claus et al., 2013), self-
monitoring strategies, opportunities to directly modify behavior, and engagement in 
informal support (Ho, 2003). Furthermore, mobile technology can reduce the number of 
patients visiting a health care facility, prioritizing care for those requiring more detailed 
medical assistance (West, 2012). Additionally, mobile technology has proven to reduce 
the burden of health care workers travelling to hard-to-reach areas to deliver care, making 
it possible to extend service to underserved areas, improve health outcomes, and promote 
medical system efficacy (West, 2012). This further helps contribute to decreased burnout 
in health care workers, as they will have fewer patients to care for during health care 
visits. 
A mobile technology with nearly 6.8 billion users is telecommunications. Indeed, 
phone contact alone is nearing 100% worldwide penetration (International 
Telecommunication Union, 2013). Telephone messages in particular are low-cost, quick 
method of intervention and are accessible and feasible even in areas where more 
intensive follow-up is not practical or available (Chen, Mishara, & Liu, 2010). Many 
patients are conscious of the benefits mobile phone assessment could bring to clinical 





2013). Moreover, telephone messages are simple to leave and retrieve, making them 
feasible for both the patient and his/her support persons (Nieuwlaat et al., 2014). 
Furthermore, telephone calls and text messages are potential avenues to meet the need for 
community-based, problem-solving interventions that are accessible to patients at a low 
cost when compared to face-to-face interventions (Beebe, Smith, & Phillips, 2014). This 
shows that mobile phone contacts have great potential in providing social support to 
patients with SMI and will be beneficial for treatment adherence. 
A very high medication adherence rate was reported in patients who received 
services in which their medications were delivered directly to them daily by a treatment 
staff (Beebeet al., 2014) as well as patients who received support from a staff in assisted 
living settings when compared to those living independently (Granholm, Ben-Zeev, Link, 
Bradshaw, & Holden, 2012). This supports the social support theory, which posits that 
social support may have positive effects on the physical, mental, and social health of an 
individual (Glanz, Rimer, & Viswanath, 2008). 
The primary objective of this integrative review was to examine literature in the 
past decade (2006-2016) on the use of mobile phone text messaging and phone calls in 
providing support to individuals with SMI with respect to increasing medication 
adherence after discharge from the hospital. Secondarily, with the social support theory 
as a guide, this review assessed social support provided to individuals with SMI through 
mobile phone contacts for core elements of the four types of social support: instrumental, 
informational, emotional, and appraisal (Glanz et al., 2008). This integrative review 





increase medication adherence in individuals with SMI after hospital discharge? (2) What 
type of social support does mobile phone contacts provide to individuals with SMI? 
Methods 
The Whittemore and Knafl (2005) integrative review framework was used for this 
review. With the guide of a reference librarian, the search terms, texting, text messaging, 
SMS, cell/mobile phone, medication adherence, medication compliance, and mental 
illness were entered into the Cumulative Index to Nursing and Allied Health Literature 
(CINAHL), the U.S. National Library of Medicine PubMed service (PubMed), 
PsycINFO, and Scopus databases to search for literature reporting on the use of mobile 
phone text messages and phone calls in medication adherence in individuals with SMI. 
Boolean operators were used to combine terms, and limiters set were humans, 2006 to 
2016, and abstracts. 
When search terms were entered into databases, Scopus generated 72 articles, 
CINAHL generated 172 articles, PubMed 122 articles, and PsyInfo 168. Additional 
records identified from manual searching of reference lists numbered 120 articles, 
making a total of 654 articles. After duplicates were removed, 338 articles remained, 
which were screened, and 260 records were excluded because they did not meet the main 
inclusion criteria. Afterward, the 78 full-text articles left were assessed, and 73 were 
excluded with reasons (32 did not address issues of medication adherence, 26 addressed 
conditions other than SMI, 15 were about substance use and eating disorders, and 1 on 
epilepsy). The main inclusion criteria were a focus of the study on the use of mobile 
phone text messages and phone calls on medication adherence in individuals with SMI. 





were also criteria for inclusion. Studies excluded were ones on children, adolescents, 
geriatric patients, patients with eating disorders, and patients with substance use 
disorders, as well as studies with primary focus on physical conditions. A total of five 
articles were included in the review. The PRISMA (Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses; http://www.prisma-statement.org) flow diagram 
of the search done is shown in Figure 1 below. 
 
Figure 1. PRISMA diagram. 






Further, this review is informed by the four types of social support: instrumental 
support, informational support, emotional support, and appraisal support (Glanz et al., 
2008). Instrumental support is explained as tangible aid and services; informational 
support as advice, suggestions, and information; emotional support as expression of 
empathy, love, trust, and care; and appraisal support as information that is useful for self-
evaluation (Glanz et al., 2008). An account of how researchers used mobile phone 
contacts to provide the four types of social support to individuals with SMI has been 
elaborated. 
Results 
General Overview of Studies Reviewed 
Five articles identified and included in this review were longitudinal studies of 
different durations, with only one (Granholm et al., 2012) being a pilot study. Most of the 
studies reviewed had participants randomly assigned to either a control or an intervention 
group (Beebe et al., 2008; Montes, Maurino, Diez, & Saiz-Ruiz, 2010; Montes, Medina, 
Gomez-Beneyto, & Maurino, 2012), with the remaining (Beebe et al., 2014; Granholm et 
al., 2012) not having a control group. Two studies used SMS only (Granholm et al., 
2012; Montes et al., 2012), one study used phone call only (Beebe et al., 2008), and one 
used both text messaging and phone calls in addition to another intervention (Beebe et al., 
2014). 
The times for text messaging/phone calls as a reminder to take medications varied 
among studies and were based on either participants’ own preferred times (Beebe et al., 
2008; Beebe et al., 2014; Montes et al., 2012) or focus group feedback (Granholm et al., 





variety of issues. Most of the studies did an assessment of medication adherence at 
baseline at the beginning of each study and at different times in the study period (Beebe 
et al., 2008; Beebe et al., 2014). Medication adherence was measured with a variety of 
validated tools (shown in a later table). 
Among the studies reviewed, most of the participants were recruited from 
outpatient facilities. Only one study (Montes et al., 2012) recruited participants ready for 
discharge from an inpatient facility. The majority of the participants were on 
antipsychotic medication (Beebe et al., 2008; Beebe et al., 2014; Montes et al., 2010). 
Others were on antidepressant medications or mood stabilizers (Granholm et al., 2012). 
Some studies also reported that some of the participants were on non-psychiatric 
medications (Beebe et al., 2008; Beebe et al., 2014). Additionally, most of the 
participants from the various studies reviewed were diagnosed with schizophrenia (any 
type), and others with affective disorder, neurotic, stress-related, somatoform disorder, 
delusional disorder, personality disorder, and behavioral disorders due to psychoactive 
substance use. Only two studies reported comorbidity with physical ailments and 
treatments given (Beebe et al., 2008; Beebe et al., 2014). 
Most of the studies reviewed addressed issues about taking medication (Beebe et 
al., 2008; Beebe et al., 2014; Montes et al., 2010), with others giving an account of 
participants’ symptoms, (Beebe et al., 2014; Granholm et al., 2012), appointment/clinic 
attendance (Beebe et al., 2014), abstaining from alcohol and other drugs (Beebe et al., 
2014), and getting along with others/socialization (Beebe et al., 2008; Beebe et al., 
2014; Granholm et al., 2012). Additionally, coping alternatives, medication adherence 





episodes of missed doses, or incomplete adherence among participants were also 
addressed (Beebe et al., 2008; Montes et al., 2010; Montes et al., 2012). Furthermore, the 
effectiveness of coping efforts (Beebe et al., 2008) and quality of life (Montes et al., 
2012) were also addressed. Moreover, one study, compared the effect of telephone calls 
only, text messages only, and both telephone calls and text messages on participants’ 
medication adherence (Beebe et al., 2014). 
Mobile Phone Contact and Medication Adherence 
Mobile phone contacts as reminders were effective in enhancing medication 
adherence in individuals with SMI (Beebe et al., 2008; Beebe et al., 2014; Granholm et 
al., 2012; Montes et al., 2010; Montes et al., 2012), with the majority of participants 
demonstrating improved medication adherence compared to baseline (Beebe et al., 
2008; Beebe et al., 2014; Granholm et al., 2012; Montes et al., 2010; Montes et al., 2012) 
although Montes et al. (2010) reported nonsignificant differences (88.2% and 90%, 
respectively) in medication adherence rate among treatment and control groups at 
baseline. SMS/phone call reminders also showed improved medication adherence among 
participants in intervention groups compared to those who received routine clinical care 
in Montes et al.’s (2010) study as follows: 8.5% increase in intervention group and only 
1.1% increase in control group at the end of the study period, resulting in 25.7% (n = 
109) improved adherence to treatment compared to 16.8% (n = 74) in the control group. 
Results from this study showed significant differences in adherence among the groups 
(96.7% of participants in the intervention group were adherent to treatment compared to 





In one study (Beebe et al. 2008), the majority of its participants lived alone (n = 
10) and were unemployed (n = 22). Moreover, in another study, participants living 
independently were initially less likely to report medication adherence because of higher 
probability of forgetting to take medication at baseline and showed high medication 
nonadherence rates compared to those in assisted living setting (Granholm et al., 2012). 
However, with the introduction of mobile phone contacts, the probability of reporting 
forgetting to take medications in participants living independently diminished over time. 
In the study, daily text messages sent as reminders to participants living independently to 
take medications increased medication adherence rate at baseline considerably when 
compared to those in assisted living where participants had support from staff and already 
showed better medication adherence rate (Granholm et al., 2012). Furthermore, higher 
medication adherence rates have also been noted in participants who had their medication 
delivered directly to them daily by treatment staff (Beebe et al., 2014). Moreover, from 
all the studies reviewed, mobile phone contacts used as reminders to take medications 
increased medication adherence at initial assessment and remained high over time for 
almost all participants. 
The only study (Beebe et al., 2014) comparing medication adherence among the 
three mobile phone contact methods (phone call only [Telephone Intervention Problem 
Solving], text message only, and text message plus phone calls) reported the percentage 
and mean standard deviation for psychiatric medication adherence scores in the first, 
second, and third month consecutively as follows: phone call only, 72 (20.1), 83.9 (18.0), 
and 80.9 (16.3); text only, 72 (33.7), 70.1 (33.2), and 71.5 (26.6); and phone call plus 





explained that the mean psychiatric adherence scores were high in both phone call only 
(by an average of 5.3%) and the text only groups (by an average of 13%) for the three 
consecutive months, these differences in medication adherence were reported to be 
nonsignificant. Furthermore, in one study (Montes et al., 2012), there were decreases in 
medication adherences rate and high numbers of hospitalizations when SMS was stopped 
in a study period. 
Mobile Phone Contact and Social Support 
With the guide of the four types of social support—instrumental support (tangible 
aid and services), informational support (advice, suggestions, and information), 
emotional support (expression of empathy, love, trust, and caring), and appraisal support 
(information that is useful for self-evaluation), as depicted by the social support theory 
(Glanz et al., 2008)—researchers used mobile phone contacts to provide social support to 
individuals with SMI as follows. 
 
Instrumental Support 
Regarding instrumental support, two studies (Beebe et al., 2014; Granholm et al., 
2012) provided participants with mobile phones and in the other three studies participants 
used their own mobile phones. In the studies reviewed all participants were sent text 
messages/SMS only (Beebe et al., 2014; Granholm et al., 2012; Montes et al., 2012), 
phone call only (Beebe et al., 2008; Beebe et al., 2014; Montes et al., 2010), or SMS plus 
phone call (Beebe et al., 2014) as reminders by nurses/researchers to take their 
medications, with one study providing additional materials (Beebe et al., 2014) to 





(Beebe et al., 2014; Granholm et al., 2012; Montes et al., 2012), weekly phone calls 
(Beebe et al., 2008; Beebe et al., 2014), monthly phone call (Montes et al., 2010), or both 
daily text messages and weekly telephone calls (Beebe et al., 2014) as means of 
providing instrumental support. 
Informational Support 
Using mobile phone contacts, researchers provided participants with education on 
how to use a mobile phone to receive calls, read text messages, and send text messages 
(Granholm et al., 2012) through mobile phone contacts. The text message/phone calls 
information received by participants focused on medications (Beebe et al., 
2014; Granholm et al., 2012; Montes et al., 2010), symptoms/mental illness (Beebe et al., 
2008; Granholm et al., 2012; Montes et al., 2012), participant attitude/perception of 
medication (Granholm et al., 2012; Montes et al., 2012), coping strategies (Beebe et al., 
2008; Beebe et al., 2014), clinic appointment/attendance (Beebe et al., 2014; Granholm et 
al., 2012), and socialization skills (Granholm et al., 2012). Participants had the 
opportunity to ask researchers questions or advice on problems concerning health care 
services or their illnesses, which were addressed immediately through advice by the 
researcher (Beebe et al., 2014). Additionally, participants received information on how to 
evaluate their medication adherence as well as symptoms severity with various validated 
instruments (Granholm et al., 2012; Montes et al., 2012). 
Emotional Support 
Researchers had the opportunity to listen to participants’ concerns, perceptions, 
awareness, understanding, and attitudes toward their mental illness and medications. 





contacts (Beebe et al., 2008; Beebe et al., 2014; Montes et al., 2012). Some studies 
(Beebe et al., 2008; Beebe et al., 2014) discussed participants’ ability to socialize and 
how participants got along with others in society. These same studies provided 
participants with answers to any questions they had and guided participants to problem-
solve difficulties encountered by generating solutions and choosing a solution. The 
researchers then followed up with participants at the next mobile phone contact to assess 
the effectiveness of the chosen solution (Beebe et al., 2008; Beebe et al., 2014). 
Appraisal Support 
Through the use of mobile phone contacts, studies reviewed (Beebe et al., 
2008; Beebe et al., 2014; Granholm et al., 2012; Montes et al., 2010; Montes et al., 2012) 
measured participants’ medication adherence behaviors. In addition to medication 
adherence, researchers assessed participants’ symptoms severity (Granholm et al., 2012); 
perception, awareness, understanding, and attitudes toward mental illness/treatment 
(Montes et al., 2012), and after-care/appointment attendance (Beebe et al., 
2014; Granholm et al., 2012). Participants’ ability to socialize (Granholm et al., 2012), 
their coping strategies (Beebe et al., 2008), and their use of alcohol and other drugs 
(Beebe et al., 2014) were also evaluated. The evaluation was done either by the support 
person or by the participants with either direct or indirect validated measures; some of 
these measures are shown in table 1. 
Benefit of Using Mobile Phone Contacts in Providing Social Support 
The results from the studies reviewed showed that mobile phone contacts 
provided numerous benefits in addition to being effective in enhancing medication 





al., 2012; Montes et al., 2010; Montes et al., 2012). Improved medication adherence was 
demonstrated in most study participants when compared to baseline (Beebe et al., 
2008; Beebe et al., 2014; Granholm et al., 2012; Montes et al., 2010; Montes et al., 
2012). When text messages were used as reminders to take medications, medication 
adherence increased in all study participants across the studies reviewed and especially in 
participants living independently when compared to those in assisted living settings 
(Granholm et al., 2012). 
There was improvement in medication adherence among participants in 
intervention groups receiving mobile phone contacts as reminders compared to those in 
the control group receiving routine clinical care (Beebe et al., 2008; Montes et al., 2012). 
Moreover, consistent with this result was a progressive increase in medication adherence 
noted in an intervention group in a 3-month study (Montes et al., 2010) after each 
telephone contact when these reminders were used. One study (Beebe et al., 2014) 
comparing the effect of telephone calls only, text messages only, and telephone calls plus 
text messages on individuals’ symptoms and medication adherence reported high 
medication adherence over a 3-month period. The study reported that those who received 
a combination of both phone call and text messages had better medication adherence than 
participants who received phone call only or text message only, although nonsignificant 
(Beebe et al., 2014). When Beebe et al. (2010) compared providing information to 
participants through text messaging and conventional writing materials, the use of SMS 
was noted to be acceptable, feasible, convenient, fast, and simple and a flexible method 





message as an adjunct to phone call should be considered in the treatment of patients with 
schizophrenia. 
Apart from mobile phone contacts increasing adherence to psychiatric 
medications, participants in the intervention groups with comorbidities who received text 
messages as reminders to take their medications showed better medication adherence for 
non-psychiatric medications when compared to the control group at baseline (Beebe et 
al., 2008; Beebe et al., 2014). However, one study had discrepant findings and showed 
nonsignificant changes in non-psychiatric medications adherence from baseline (Beebe et 
al., 2008). 
In some studies, other participants issues that were affected by medication 
adherence were assessed, and it was observed that when medication adherence improved, 
participants’ symptoms (Beebe et al., 2014; Granholm et al., 2012; Montes et al., 2010), 
awareness of mental illness (Granholm et al., 2012), attitude/perception of the benefits of 
medication adherence (Granholm et al., 2012; Montes et al., 2012), appointment 
attendance (Beebe et al., 2014; Granholm et al., 2012), and socialization skills also 
improved (Granholm et al., 2012) among individuals with SMI. 
Table 1 includes general characteristics of studies reviewed: author, country of 
study, type of study/duration, diagnoses, type of treatment facility, sample characteristics/ 






Table 1. General Characteristics of Study Reviewed 


























N = 30 Pill count Both psychiatric and non-
psychiatric medication 
adherence was higher in 
the phone call (TIPS) plus 
text group than both the 
phone call only and the 
text only groups, but these 
differences were not 
significant in psychiatric 
medication adherence. 
  19 females 
  11 males 
No control group  Schizophrenia 
(any subtype) or 
schizoaffective 
disorder 



















N = 55 Medication 
Adherence 
Questionnaire 
There was better 
improvement in medication 
adherence in participants 
and significantly in 
participants living 
independently when 
compared to those in 
assisted living facilities. 
 Age ˃ 18 years 
No control group Schizophrenia; paranoid = 
32, undifferentiated = 10, 
disorganized = 2, 












month study (October 
2006-November 2007) 




N = 865 Register of 
Adherence to 
Treatment 
There were significantly 
higher patients followed up 
with phone calls being 
adherent to medications 
than those in the control 
group, with significant 
improvement in adherence 
in antipsychotic 
medications. 
Control group = 441 
Intervention group = 424 
≥18 years old 
 
Clinically stable outpatient 


















Persons receiving phone 
calls (TIPS) had 
significantly higher 
adherence to psychiatric 
medications throughout the 
study period compared to 
13= control 






















those receiving usual care. 
Phone calls should be used 

















N = 254 Medication 
Adherence 
Questionnaire 
There was significantly 
greater improvement in 
adherence among patients 
receiving text messages 
compared to the control 
group from baseline. 
18-65 years of age 









A key finding of this review was that mobile phone contacts (text 
messaging/phone calls) have been used to promote medication adherence in individuals 
with SMI, and the studies reviewed showed that mobile phone contacts, especially text 
messages, were effective in reminding study participants to take their medications (Beebe 
et al., 2008; Beebe et al., 2014; Granholm et al., 2012; Montes et al., 2010; Montes et al., 
2012). These results were noted in similar studies (Kunigiri, Gajebasia, & Sallah, 2014; 
Montes, Maurino, Diez, & Saiz-Ruiz, 2011; Van Gent & Knoppert Van Der Klein, 2010). 
Moreover, for all the studies reviewed, the use of mobile phone contacts achieved higher 
medication adherence rates across all the studies. This result is supported by similar 
studies (Stentzel et al., 2015; Vervloet et al., 2012). One other cardinal observation noted 
in this review was the high medication adherence rate shown when text messages were 
used as an adjunct to other interventions. This typically included a combination of the 
following: phone call, text message, or conventional material (printed material; Beebe et 
al., 2014). The results showed greater increase in medication adherence rates in 
individuals with SMI when a combination of multiple interventions occurred compared to 
any method used independently. 
Furthermore, one study showed that text messages are noncumbersome and 
inexpensive in providing support for individuals with SMI (Beebe et al., 2014). The study 
also proved text messages/SMS to be accessible, feasible/convenient, low-cost, fast, 
simple, quick, and more effective in providing information on medication adherence 
when compared to traditional/conventional printed materials. These findings are 




Dixon, & Himelhoch, 2011; Granholm, Loh, & Swendsen, 2008; Harrison et al., 2011; 
Johnson et al., 2009; Mäkelä, Paavola, & Stenman, 2010; Patrick, Griswold, Raab, & 
Intille, 2008; Pijnenborg et al., 2010; Spaniel et al., 2008; Van den Berg, Graba, 
Freyberger, & Hoffmann, 2011). Also, considering that the researchers were able to 
continue following up with most participants through the study period, Beebe et al.’s 
(2014) assertion that mobile phone contacts are acceptable to both the support person and 
the participant is laudable. 
Additionally, studies reviewed showed that individuals on psychiatric medication 
treatments with comorbidities requiring and taking both psychiatric and non-psychiatric 
medications had mixed results: High medication adherence was noted for psychiatric 
medications but nonsignificant adherence results for non-psychiatric medications (Beebe 
et al., 2014). Comparable results were noted in Patrick et al. (2008) and Smith and Schatz 
(2010) studies but incongruent with results of Pratt et al. (2006) and Dolder, Lacro, and 
Jeste (2003) study where high medication adherence rate were noted for both psychiatric 
and non-psychiatric medications. Moreover, when patients’ medication adherence is 
monitored, the expectation is that all medications would have been adhered to. 
Considering that participants had better adherence with psychiatric medications but low 
adherence to non-psychiatric medications makes it a cause for concern. The question is, 
were participants adhering to the psychiatric medications because they knew they were 
being evaluated purposely on psychiatric medications and not non-psychiatric 
medications? The reason for this unusual low adherence rate needs further study. 
Regarding the core domains of the social support theory, studies reviewed showed 




medication adherence. The social support mobile phone contacts provide to individuals 
with SMI, especially the use of text messages, should not be underestimated. Studies 
reviewed showed that individuals with SMI were given tangible aid and services, advice, 
suggestions, and a variety of information including information for self-evaluation as 
described by Glanz et al. (2008). Even though the use of the social support theory was not 
mentioned explicitly in the studies reviewed, the account given by these studies is 
consistent with the theory’s core domains. Mobile phone contacts proved to promote 
autonomy, which is one of the important fundamentals of mental health treatment. 
Instrumental Support 
Participants in the studies reviewed received tangible aid and services such as 
mobile phones (Beebe et al., 2014; Granholm et al., 2012) and reminders through text 
messages or phone calls. In addition, participants received reminders based on their own 
preferred times (Beebe et al., 2008; Beebe et al., 2014; Montes et al., 2012) or from focus 
group feedback (Granholm et al. 2012). This sort of assistance can be seen as “perceived 
control” noted in the social support theory (Glanz et al., 2008). 
Informational Support 
Individuals with SMI were given advice, suggestions, and information through 
mobile phone contacts. From the studies reviewed, a support person had the opportunity 
to address questions or other problems participants were facing (Beebe et al., 2008; 
Beebe et al., 2014). The person providing support identified participants’ reasons for the 
nonadherence and immediately provided advice and referrals necessary (Beebe et al., 




Considering what has been discussed so far, participants got the help they needed, 
and rehospitalization was prevented, which is consistent with the aims of the social 
support theory. The social support theory confirms that when people experience stressors, 
enhanced individual/community resources increase the likelihood that the stressors will 
be handled/coped with in a way that reduces the long-term or short-term adverse health 
consequences (Glanz et al., 2008). Indeed, providing social support to individuals with 
SMI is recommended for continuing treatment since individuals with SMI will not left 
alone to go through challenges, which can lead to medication nonadherence, increased 
symptoms, and rehospitalizations. 
Another goal of the social support theory that was addressed is reduction in 
uncertainty or unpredictability and production of desired outcomes (Glanz et al., 2008). 
Noted in the studies reviewed, individuals with SMI were provided with advice and 
referrals through mobile phone contacts, resulting in reduction in severity of participants’ 
symptoms, reduction in rehospitalization, and increase in medication adherence 
outcomes, which is consistent with the goal of the social support theory. To further 
emphasize the importance of using mobile phone contacts in providing social support to 
individuals with SMI, one undesirable outcome noted in this review was a decrease in 
medication adherences rate and high numbers of hospitalizations when text messages 
were stopped in a study period (Montes et al. 2012). These findings therefore support the 
view that mobile devices increase medication adherence across diverse health and mental 
health problems (Heron & Smyth 2010; Kunigiri et al., 2014; Van den Berg, Grabe, 






Researchers could express empathy, love, trust, and care to individuals with SMI 
through mobile phone contacts. Participants’ concerns, perceptions, awareness, 
understanding, and attitudes toward their mental illness and medications were addressed 
by the researchers (Beebe et al., 2008; Beebe et al., 2014). Additionally, the participants’ 
ability to socialize and get along with others were assessed (Beebe et al., 2008; Beebe et 
al., 2014). Researchers guided participants to problem-solve difficulties encountered and 
assess the effectiveness of the solution (Beebe et al., 2008; Beebe et al., 2014). This 
confirms that the availability of enhanced individual/community resources promotes the 
likelihood that people experiencing stressors will cope in a way that adverse health 
consequences will be decreased or prevented (Glanz et al., 2008). 
Appraisal Support 
All the studies reviewed (Beebe et al., 2008; Beebe et al., 2014; Granholm et al., 
2012; Montes et al., 2010; Montes et al., 2012) used assessment tools that are well known 
in mental health research for measuring medication adherence (Brain et al., 2014; Byerly 
et al., 2008; Kikkert et al., 2011; Thompson, Kulkarni, & Sergejew, 2000). In some 
studies, participants were taught how to assess their own medication adherence and 
symptom severity (Beebe et al., 2008; Beebe et al., 2014). This method increased 
participants’ autonomy in that they could identify where they were in their recovery 
process and were more willing to adhere to treatment. This finding supports Palmier-
Claus et al.’s (2013), Kunigiri et al.’s (2014), Vervloet et al.’s (2012), and Stentzel et al.’s 




Additionally, when participants’ medication adherence rates improved using 
mobile phone contacts, their symptoms, attitude, and perception toward medication 
adherence, appointment attendance, and socialization also improved (Beebe et al., 2014; 
Granholm et al., 2012; Montes et al., 2010; Montes et al., 2012). These findings support 
similar studies (Car, Gurol-Urganci, de Jongh, Vodopivec-Jamsek, & Atun, 2012; 
Fortney et al., 2013; Van den Berg et al., 2015) as well as the social support theory 
(Glanz et al., 2008). 
The Effect of Mobile Phone Contact Support and Medication Adherence in SMI 
It is important to note that all studies reviewed elaborate the beneficial effect of 
mobile phone contacts in providing support to individuals with SMI by increasing 
participants’ medication adherence, improving symptoms, improving ability to socialize, 
and developing better attitude toward mental health. To support this finding better, it was 
seen that there was decrease in medication adherences rate and high numbers of 
hospitalizations when text messages were stopped in a study period (Montes et al., 2012). 
However, looking closely at the studies reviewed, most of the study participants were 
recruited from outpatient settings, with only one study (Montes et al., 2012) recruiting 
participants ready for discharge from an inpatient facility, which may increase medication 
nonadherence if the patient had not had support after discharge. 
Waiting to contact patients at their outpatient facilities may not address issues of 
medication adherence in all patients discharged from the hospital. This is because some 
patients discharged who are confused about their medications may end up nonadherent 
and may be re-hospitalized before their first outpatient appointment since immediate 




for discontinuing their therapy due to frequent long waiting periods for consecutive 
appointments in the ambulatory care system (Van den Berg et al., 2015). It is therefore 
imperative for mental health professionals to recognize that issues of medication 
nonadherence in individuals with SMI should be addressed immediately following 
hospital discharge. 
Also noted in this review is that some participants were already receiving support 
either by having their medications directly delivered to them or by living in assisted 
settings (Beebe et al., 2014; Granholm et al., 2012), and the intervention may have only 
served as a buffer to their medication adherence behavior. For this reason, it should be 
noted that even though there is high medication nonadherence rate in individuals with 
SMI, there is the likelihood that most patients with mental issues would adhere to their 
medications if given the necessary support. To support this statement, El-Mallakh and 
Findlay (2015) brought to light that lack of family support for adherence, or having no 
family, further contributes to nonadherence in patients with mental illness. This makes it 
very important to identify a person whom the patient perceives as a social support 
(Sawant & Jethwani, 2010) when the individual is admitted to an inpatient setting before 
discharge. This allows continuity of care and recovery through early identification of 
problems and the application of solutions to address any problems the patient may 
encounter immediately after discharge. 
However, considering studies reviewed, it is difficult to attribute the increase in 
medication adherence to the support provided through mobile phone contacts intervention 




There is, therefore, the need to apply this support intervention to patients who are known 
to be nonadherent to their medications and/or have no structured support. 
Authors of studies reviewed noticed some limitations of the studies. Some studies 
reviewed made it known that the use of small sample sizes in their studies prevents 
generalization of study results (Beebe et al., 2008; Beebe et al., 2014). One study noticed 
a possibility of a Type II error as smaller than expected increases in medication 
adherence resulted in power less than 35% to detect significant differences in adherence 
(Beebe et al., 2014). Furthermore, the inability to identify significant relationships in the 
intervention given and outcome due to lack of power was addressed (Beebe et al., 2008). 
However, other studies used larger sample sizes and obtained remarkable results (Montes 
et al., 2010; Montes et al., 2012). 
A possible selection bias was raised in studies reviewed as most participants 
included in the studies were clinically stable (Granholm et al., 2012; Montes et al., 2012), 
taking antipsychotic medications, and adherent (Beebe et al., 2008; Granholm et al., 
2012; Montes et al., 2012) at baseline. To be more explicit, some participants who were 
already on depot medications (Beebe et al., 2014) and those with less clinical symptoms 
(low severity of voices and multiple social interactions) at baseline were included in the 
studies (Granholm et al., 2012). Excluded from some studies were less stable or unstable 
patients with symptoms of severe paranoid delusions or hallucinations (Montes et al., 
2012). Moreover, some researchers believed that the exclusion was necessary because 
participants could be unwilling to participate or the intervention (SMS reminders) could 
even worsen their clinical status (Montes et al., 2012). This aligns with Beebe et al.’s 




due to instability. This is congruent with the report of some studies that most nonadherent 
patients were reluctant to participate in the studies because recruitment methods used 
leaned toward more adherent patients (Beebe et al., 2008; Montes et al., 2012). 
Moreover, such exclusions are noted to be a threat to the internal validity of a 
study (Beebe et al., 2008), and inclusion of less stable/unstable patients at baseline could 
show greater improvements in outcome (Granholm et al., 2012). Furthermore, the use of 
one-size-fit-all timing of the application of the intervention is noted in one study to be 
problematic. Participants who take medications outside of the scheduled intervention 
time may not benefit due to the fixed scheduling (Montes et al., 2012). Furthermore, 
nonblinding of researchers applying an intervention could have led to high rating of 
greater improvement in adherence and symptoms severity (Montes et al., 2012). 
Authors raised concerns about the reliability of measures used to assess 
medication adherence that is both objective and subjective. Challenges reported regarding 
subjective measures such as self-rated scales was the tendency of participants 
inflating/overestimating self-report of medication adherence (Granholm et al., 2012; 
Montes et al., 2012). This inflation is attributed to either social desirability of the 
participants or rater expectations (Montes et al., 2012). Objective measures such as pill 
counts’ inability to confirm/guarantee that missing medications were truly ingested 
(Beebe et al., 2008; Beebe et al., 2014) is problematic even though it is noted to be 
acceptable to patients (Beebe et al., 2008) and seen as a more objective measure 
(Granholm et al., 2012). 
Some variables noted to be essential for medication adherence or nonadherence 




with therapist or clinician, less outpatient contact (Montes et al., 2010), as well as 
participants’ prior experiences with antipsychotic treatments and side effects were not 
assessed (Montes et al., 2012). Similarly, the effects of the intervention (mobile phone 
contact) on participants’ specific beliefs about medications, socialization, and auditory 
hallucinations were not assessed in one study (Granholm et al., 2012). Even though some 
studies (Beebe et al., 2008 Montes et al., 2012) noticed greater improvement in 
medication adherence in the intervention group when compared with control group 
receiving routine clinical care, one study lacked a comparison group (Granholm et al., 
2012) and recommends comparison groups in mobile phone contact interventions. 
Granholm et al. (2012) acknowledge that the use of incentive for responding to an 
intervention is not feasible in the real world. 
From studies reviewed, authors made the following important recommendations 
to improve future text messages and phone calls intervention research to improve 
medication adherence: (a) assessment of participants’ insight and environmental factors 
of nonadherence to establish the benefit of the intervention in patients at risk (Montes et 
al., 2010), (b) the use of time-lagged analyses to examine the relationships between 
mobile interventions and specific patient beliefs in a larger population (Granholm et al., 
2012), (c) the use of both objective and subjective methods to assess medication 
adherence (Granholm et al., 2012; Montes et al., 2012), and (d) the need to determine text 
messaging response rates and medication adherence without incentives (Granholm et al., 
2012). 
Readers are warned by some authors (Beebe et al., 2008; Granholm et al., 2012) 




Furthermore, there is a need for further studies to identify reasons for 
nonsignificant differences in medication adherence rates even though there are significant 
improvement in symptoms in one study that compared the mobile phone contact methods 
(call, text, and call plus text). Additionally, more studies on patients who are recruited 
and followed from inpatient settings should be done. Furthermore, the population of SMI 
was disproportionately studied as majority of participates in this review had 
schizophrenia. There is the need for more studies on the use of mobile phone contacts for 
improving medication adherence in patients with SMI with diagnoses other than 
schizophrenia. 
A study on the comparison of mobile phone contacts use on medication adherence 
in individuals with SMI from inpatient settings and those from outpatient settings is 
needed as this will help determine whether time is a crucial factor in the introduction of 
the intervention in enhancing medication adherence in individuals with SMI. 
Last, slight differences exist in variables measured apart from medication 
adherence in studies reviewed. Beebe et al. (2008) while applying their text messages and 
phone calls intervention also provided participants with advice and problem-solving 
guide and measured symptoms. Montes et al. (2010) targeted participants’ symptoms 
severity and quality of life in addition to medication adherence. Granholm et al. (2012) 
on one hand sort participants’ socialization skills, auditory hallucinations, and medication 
adherence. Montes et al. (2012) on the other hand looked at participants’ attitude toward 
medication, insight into illness, clinical severity, and health-related quality of life after 
the application of the intervention. Beebe et al. (2014) mainly studied participant 




reviewed apart from medication adherence was participants’ symptom severity. 
Considering study results showing improvement in these variables, a combination of into 
one intervention research will be beneficial in increasing medication adherence in 
individuals with SMI. 
This integrative review has some important limitations. First, although a 
comprehensive literature search was done, only five studies relating to mobile phone 
contacts and medication adherence in individuals with SMI were identified. This was true 
considering that mobile technology use to improve mental health services among 
individuals with serious mental illness remains doubtful (Ben-Zeev, Davis, Kaiser, 
Krzsos, & Drake, 2013). Second, this review did not take into consideration the 
level/severity of participants’ mental illness prior to participating in the respective 
studies. Last, this review lumped together the social support provided by all the mobile 
phone contact methods to increase medication adherence in individuals with SMI to draw 
conclusions on the four types of social support. Furthermore, this review did not consider 
individual mobile phone contact method (text message only, phone call only, or text 
message plus phone call) for the core elements of the four types of social support 
described by Glanz et al. (2008). This will be done comprehensively in a future study. 
Conclusion 
Notwithstanding the gaps in literature reviewed, the use/benefit of mobile phone 
contacts, especially SMS, as means of providing social support for individuals with SMI 
is notable. This review illustrates the positive effects of social support on the physical, 
mental, and social health of individuals with SMI as depicted by the four types of social 




Mobile phone contacts use to provide social support proved to be acceptable to both the 
individual and support persons because of its feasibility, convenience, speed, simplicity, 
and flexibility. 
The key factor noted to have enhanced mobile phone contacts to increase 
medication adherence in individuals with SMI was autonomy. Participants had a say in 
the intervention by choosing the time they wanted the intervention to occur. It is possible 
that adherence to medications was increased partly because participants had autonomy 
and felt part of their treatment. Additionally, with the convenience and acceptability of 
mobile phone contacts, mental health professionals will be able to provide individuals 
with SMI support after hospital discharge by providing education (awareness) and 
assessment (medication adherence, symptom severity, appointment attendance, means of 
socializing), as well as providing referrals when appropriate especially in individuals 
living independently. Also, it was mentioned in studies reviewed that mobile phone 
contacts especially text messaging provides a better means to communicate health 
information to individuals with SMI than the conventional means (print). Additionally, 
text messages could be used as an adjunct to other interventions to improve medication 
adherence in this population. 
In conclusion, although the studies reviewed showed increases in medication 
adherence rate of study participants when mobile phone contacts were used to provide 
support, the total number of participants (sample size) used in the five studies reviewed is 
not enough to provide conclusive evidence about the effectiveness of mobile phone 
contact in increasing medication adherence in this population. Therefore, there is the need 




optimal timing of the use of SMS (e.g., immediately after discharge) as well as issues of 
dosing and the comparative effectiveness of the different mobile phone contact delivery 
methods (calls only, text messages only, and calls plus text messages) in providing 
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A Descriptive Correlational Study: Mental Health Service Users Mobile Phone Contact 
Method Preference and Medication Adherence. 
 
Abstract 
INTRODUCTION: Medication non-adherence in mental health service users has been 
attributed to both intentional and unintentional causes. Mobile phone contact (MPC) can 
potentially increase medication adherence and improve overall health outcomes. 
However, lack of data exists regarding participants’ preferred mobile phone contact 
method (phone calls only, text messages only or text message plus phone calls) and its 
relationship with medication adherence. 
 
METHODS: This descriptive correlational study used a survey approach (interview) to 
collect data from participants receiving mental health services at an outpatient mental 
health facility. Convenience sampling was used to enroll 41 study participants. 
 
RESULTS: Text messaging was the preferred method of contact by participants with 
70.7% choosing this method. Reasons for this choice included; convenience, less time 
consuming, less distractive, and simple to use. No relationship was noted in MPC 
preference with medication adherence or participants’ demographic/clinical data except 
ethnicity.  
 
CONCLUSION: This study suggests that participants receiving mental health services 
that receive mobile phone contact (MPC), prefer text messaging when receiving support 
to increase medication adherence after discharge. This preferred method of MPC may 






Introduction and Background 
Mental illnesses and substance-related/addictive disorders are chronic conditions 
that substantially impact public health (Lee et al., 2015; SAMSHA, 2017). The use of 
medications continues to be an important element in the treatment of mental illnesses 
(Buchanan et al., 2010; Velligan et al., 2009) and substance use disorders (Lee et al., 
2015). When medications are taken as prescribed medicine can reduce the severity of 
mental illness and improve outcomes (Velligan, Sajatovic, Hatch, Kramata, & Docherty, 
2017). Benefits of medication use in substance/alcohol use disorders include: (a) 
reduction in substance use, (b) prevention of overdose, (c) medical management of 
withdrawal or detoxification, (d) relapse prevention, and (e) maintenance of remission 
(Lee et al., 2015).  
Although the use of medicine aids with reducing substance/alcohol use disorders, 
medication nonadherence is a concern and frequently occurs shortly after hospital 
discharge (Tomko et al., 2013; Van Dorn et al., 2012). Furthermore, medication 
nonadherence  leads to negative consequences such as poorer treatment outcomes (Lee et 
al., 2015; Spaniel et al., 2008), substantial negative impact on patients’ health and 
functioning (Higashi, 2013; Nath, 2012; Tomko et al., 2013), higher hospitalization rates 
(Najt, 2011; Uhlmann, Kaehler, & Harris, 2014), and increased cost (Morken, Widen, & 
Grawe, 2008; Van den Berg et al., 2015; SAMSHA, 2017). 
Causes of Medication Non-adherence 
Medication nonadherence has been attributed to both intentional and unintentional 
causes (Velligan et al., 2017). The intentional causes of medication nonadherence include 




symptom severity, (e) stigma, and (f) negative therapeutic alliance (Lam et al., 2013; 
Novick et al., 2010; Wong et al., 2015). However, reasons such as cognitive impairments 
(Alene et al., 2012; Ascher-Svanum et al., 2006; Sajatovic et al., 2011), substance use 
(Alene et al., 2012; Eticha et al., 2015; Jonsdottir et al., 2013; Zeber et al. 2011; ), severe 
depression/antidepressant use (Ascher-Svanum et al., 2006; Na et al., 2015;), poor 
family/social support (Morken, Grawe, & Widen, 2007; Rabinovitch et al., 2009), 
inactive social functioning and independent housing (Elbogen et al., 2005; Novick et al., 
2010), as well as poor access to mental health care (McCann et al., 2008; Zeber et al., 
2011) have been attributed to unintentional causes of non-adherence. 
Mental Health and Support  
When patients are discharged from the hospital, they need support despite 
apparent recovery (Bickley et al., 2013). The numerous barriers encountered by 
individuals after discharge such as transportation, difficulties in making medical 
decisions, managing personal health problems, and troubling mental health symptoms 
(Nath, Wong, Marcus, & Solomon, 2012) make providing support for these individuals in 
real time essential. Research has shown that individuals with mental health problems 
often receive support from a core social network of family and friends as well as 
coworkers, neighbors, acquaintances, extended kin, and friendships (Perry, 2011). Yet, if 
an individual’s mental health problems provoke fear and discomfort (Green et al., 2002, 
Perry, 2011) a person can become potentially burdensome to these otherwise supportive 
networks.  
This burden can strain social connections leading to lack of social support (Bright, 




suggested that individuals who seek mental health support begin treatment with larger 
and more broadly functioning social networks, but the size of a social network decreases 
over time. However, support is important to mitigate the many barriers faced by 
individuals with mental health problems. 
Indispensable Nature of Support in Mental Health Treatment 
Continuous long-term medication treatment with close monitoring and real-time 
symptom assessment for early and immediate intervention is beneficial for individuals 
with mental health challenges (Ainsworth, Palmier-Claus, Machin, & Barrowclough, 
2013). Moreover, discharge planning is essential to achieve continuous long-term 
medication treatment. Additionally, discharge planning has numerous benefits that 
include: (a) increases in medication adherence after discharge, (b) decreases in clinical 
symptoms, and (c) reduction in the frequency of hospitalizations (Hamann et al., 2014; 
Khaleghparast et al., 2004; Pantalon et al., 2014). Furthermore, effective discharge 
planning increases outpatient treatment and continuity of care, reduces readmission rates, 
and overall improves mental health outcomes and quality of life for patients (Schulz, 
Gray, & Spiekermann, 2013). Because the support network in this population decreased 
with time, healthcare professionals might include readily available telecommunication 
systems in discharge planning to provide support and potentially enhance medication 
adherence.  
Mobile Phone Contacts and Support 
Telecommunication technology has over 6.8 billion users nearing 100% 
worldwide penetration (Chen, Mishara & Liu, 2010; International Telecommunication 




health problems is estimated to be between 73% to almost 100% (Ennis, Rose, & Denis, 
2012) with cell phone ownership comparable with ownership among a nationally 
representative sample in the United States (Campbell, Caine, Connelly, Doub, & Bragg, 
2015). Studies indicate that support provided through cell phone/ mobile phone contacts 
(MPC) is feasible and inexpensive for enhancing medication adherence in this 
population. In addition, support through MPC provided frequent long-term treatment and 
close monitoring of mental health service users (Chen, Mishara, & Lui, 2010; Klasnja & 
Pratt, 2012; National Institute of Mental Health, 2015), which is needed to enhance 
medication adherence in this population. MPC can include phone calls (PC) or text 
messages (TM).  TM is noted to be usually quick and accessible to patients even in areas 
where more intensive follow-up is not practical or available (Chen et al., 2010). 
Moreover, TM is not limited by the model or make of an individual’s phone (Klasnja & 
Pratt, 2012).  
MPC and Medication Adherence in Mental Health 
Studies that used MPC to increase medication adherence in individuals with 
mental health challenges examined three delivery methods: phone call only (PC), text 
messages only (TM); or a combination of phone call plus text messages (TMPC) 
individually and in combination (Beebe, Smith, & Philip, 2014; Beebe et al., 2010; 
Granholm, Ben-Zeev,  Link, Bradshaw, & Holden, 2012; Montes, Maurino, Diez, & 
Saiz-Ruiz, 2011,2010) with other materials. Investigators found increases in medication 
adherence when individuals with mental illness (MI) received reminders, education, and 




This result was also noted in individuals living independently as well as those previously 
noted to be non-adherent to their medications (Granholm et al., 2012).  
With support through MPC, increases in medication adherence improved 
participants’ symptoms, increased appointment/clinic attendance, improved the ability to 
socialize, and reduced hospital readmissions (Beebe et al., 2014; Granholm et al., 2012; 
Montes et al., 2011; Najt, 2011; Uhlmannet et al., 2014). Further, barriers to medication 
adherence such as forgetfulness, lack of knowledge about prescribed medications (Beebe 
et al., 2010; Montes et al., 2010), missed doses or incomplete adherence (Montes et al., 
2011) after discharge were addressed.  Additionally, TM alone extensively improved 
medication adherence (Agyapong, Milnes, & McLoughlin, 2013; Branson, Clemmey, & 
Mukherjee, 2013; Foreman et al., 2012; Granholm et al., 2012; Harrison et al., 2011), 
especially in reminding patients about medications (Kunigiri, Gajebasia, & Sallah, 2014). 
Moreover, when TM was stopped in one study the participants’ medication adherence 
rates decreased and hospitalizations increased (Montes et al., 2010).  
Identified Gap in Research 
Even though MPC is a promising tool in providing support to increase medication 
adherence in individuals with mental health problems, limited studies exist evaluating the 
use of this tool. The few studies (Beebe et al. (2008) and Beebe et al. (2014) and 
Granholm et al. (2012) and Montes et al. (2010), and Montes et al. (2012) that used MPC 
to provide support to increase medication adherence in this population had limitations 
needing further research. One limitation is that, even though participants chose preferred 
times for receiving MPC, lack of evidence exists on whether participants preferred the 




Likewise, in one study Beebe et al. (2014) comparing the three methods of MPC showing 
increases in medication adherence in the group receiving TMPC, there was no evidence 
that the participants actually preferred that method. However, studies show that 
considering patients preferences in mental health improved clinical outcomes (Raue, 
Schulberg, Heo, Klimstra, & Bruce, 2009; Kocsis, Leon, & Markowitz, 2009; Gelhorn, 
Sexton, & Classi, 2011) and thus identifying preferences for MPC method may lead to 
further improvement in medication adherence. 
The main objective of this study was to identify the MPC delivery method MHS 
users prefer when receiving support to increase medication adherence after discharge.  
Further, this study explored the relationship among MHS users’ preferred MPC delivery 
method, demographic/illness characteristics, medication adherence rate, and the overall 




Social support theory postulates that social support has a positive impact on the 
physical, mental, and social health of individuals (Glanz, Rimer, & Viswanath, 2008). 
There are four types of social support: instrumental (tangible aid and services), 
informational (advice, suggestions and information), emotional (expression of empathy, 
love, trust, and caring), and appraisal (information that is useful for self-evaluation) 
(Glanz et al., 2008).  
Bright, (2018) noted how researchers who used MPC provided participants with 




received mobile phones (Beebe et al., 2014; Granholm et al., 2012) and text messages 
and/or phone calls reminders (Beebe, et al., 2008; Montes et al., 2012). Informational 
support was provided by addressing questions and problems participants were facing 
(Beebe et al., 2008; Beebe et al., 2014). Emotional support was provided to participants 
when concerns, perceptions, awareness, understanding, and attitudes toward their mental 
illness and medications as well as the ability to socialize with others as suggested by 
(Beebe et al., 2008; Beebe et al., 2014). In addition, appraisal support was provided when 
participants were given the opportunity to assess their medication adherence and compare 
the adherence to real time medication adherence with well-known medication adherence 
assessment measures (Beebe et al., 2008; Beebe et al., 2014; Granholm et al., 2012; 
Montes et al., 2010; Montes et al., 2012).  
However, lack of evidence exists regarding MPC method preference among 
individuals receiving MHS. Moreover, the need to identify patients’ preferences cannot 
be over emphasized in mental health treatment. Integrating patient preferences into 
treatment is an expectation (Papakostas, 2009; Sobczak, 2009), because integration 
provides a positive relationship with treatment initiation and adherence (Raue, Schulberg, 
Heo, Klimstra, & Bruce, 2009). Further, understanding a patient’s preferences is noted to 
result in favorable outcomes (Gelhorn, Sexton, & Classi, 2011). For example, in a 
depression study, patients receiving treatment based upon preferred intervention had 
lower outcome depression scores compared to those who did not (Kocsis, Leon, & 
Markowitz, 2009). This study suggests the importance of assessing participants’ 
preference in MPC methods when receiving support to increase medication adherence 





This descriptive correlational study utilized a survey approach with cross-
sectional design to examine the perceptions of participants receiving mental health 
services on the value of MPC use to enhance medication adherence. A convenience 
sample was used to recruit study participants 18 years of age and older. All clients at an 
outpatient facility located in Virginia were given the opportunity to participate in the 
study to ensure appropriate representation of all ages, races, and diagnoses. Participants’ 
demographic information were reported in the analysis. Moreover, the clinic director, 




The mental health facility located in Virginia provides both inpatient and 
outpatient services to adolescents and adults with mental health and substance abuse 
diagnoses. The facility’s outpatient services include intensive outpatient services, partial 
hospitalization, and outpatient services. Study participants were recruited from the 
outpatient service. 
Participants 
In this study, participants were recruited who had a diagnosis of a mental illness 
(MI) including schizophrenia (any type), bipolar disorder, major depression disorder, 
schizoaffective disorder, obsessive-compulsive disorder, panic disorder, post-traumatic 
stress disorder, and substance use disorder as specified by Diagnostic and Statistical 




years and 70 years, able to communicate in English, and taking at least one type of 
psychiatric medication. Every potential participant who presented at the outpatient 
facility for treatment during the data collection period was given the opportunity to 
participate in the study, ensuring the inclusion of participants of all racial and gender 
backgrounds.  
Procedures for Data Collection 
After reviewing charts, individuals who met inclusion criteria were identified as 
potential participants. One of the individual’s treatment team members (either director, 
counselor, or program manager) introduced the researcher to the eligible individual. 
Eligible individuals were informed about the purpose of the study and were provided 
with contact information and informed that participation in the study was voluntary as 
well as they had the right to withdraw from the study at any time without an impact on 
treatment in any way.  
Once consented, the researcher scheduled at least 20 minutes for each interview and 
audio-taped the interview. The researcher conducted the interviews in a private 
comfortable room provided by the outpatient facility. During this time the researcher 
administered the demographic questionnaire, medication adherence questionnaire, and 
structured interview guide.  
The PI assessed participants’ medication adherence with the medication 
adherence questionnaire (MAQ). The PI then asked participants about MPC method 
preferences, the reason for this choice, and perceptions of the benefits and problems with 
MPC. Participants were also asked to choose a second and third MPC delivery method 




foresee arising when receiving support through MPC and how to avoid or overcome these 
perceived problems.  In addition, the researcher read the questions, answer choices to 
participants, and recorded any other comments the participants had verbatim on the 
interview guide. The PI also recorded the participants’ demographic information from the 
participants’ chart. Recruitment and interviews were conducted from December 2017 
through January 2018. Recruitment was concluded after all the potential participants were 
approached. 
Sample size 
The researcher contacted 76 prospective participants, 35 prospective participants 
were not enrolled in the study, 19 out of the 35 did not meet criteria for inclusion, and the 
remaining 16 refused to participate in the study. Reasons for not meeting inclusion 
criteria and refusal to participate in the study are elaborated in a flow chart in the analysis 
section. A total of 41 participants were enrolled in the study.  
Outcome measures 
Outcomes measured in this study included participants’ medication adherence, 
participants’ MPC preference, and the overall acceptability of MPC. The PI assessed 
participants’ medication adherence with the medication adherence questionnaire (MAQ). 
The MAQ is a 4-item self-administered medication adherence scale that has been used as 
a medication adherence measure since 1986 (Morisky, Greene, & Levine, 1986). The 
MAQ requires a simple yes or no answer to measure medication adherence. Questions 
asked on this scale included: do you ever forget to take your medicine? Are you careless 
at times about taking your medicine? When you feel better do you sometimes stop taking 




stop taking it? The score ranges from zero to four and was interpreted as follows: 0= 
Highest adherence, 1 and 2 = medium adherence, and 3 and 4 = low adherence. Zero 
depicted the highest adherence levels and four the lowest adherence. 
Participants’ MPC method preference was assessed along with overall 
acceptability, mobile phone ownership/possession, current use of MPC reminders to take 
medications (if receiving reminders through which means and if preferred), willingness to 
receive support through MPC, problems foreseen with receiving MPC intervention and 
solution to these problems.  
Ethics  
The Institutional Review Board at the Medical University of South Carolina 
(MUSC) approved this study. Institutional approval also was given by the outpatient 
facility. The researcher conducted the interviews in a designated private and comfortable 
room provided by the facility. The researcher explained details of the study including, 
medication adherence assessment, obtaining of demographic information, and interview 
requirements (including audio recording and verbatim hand recording on interview guide) 
to participants. Additionally, the PI made participants aware of the need for written 
informed consent and Health Insurance Portability and Accountability Act of 1996 
(HIPAA) authorization forms. The PI made participants aware of the right to withdraw 
from the study at any time and that any treatment received will not be affected in any 
way. Furthermore, participants were assured of the confidentiality of the information.  
All data collected, which included demographic information questionnaires, 
medication adherence questionnaire, informed consent documents, HIPAA documents, 




compartments, then transferred electronically immediately to a password protected 
Research Electronic Data Capture (REDcap) environment. REDcap is a secure web-
based application designed to support data capture for research studies (Harris et al., 
2009), provided by MUSC. Further, the code-linked data was transferred and stored in 
Box (an electronic file sharing and storage system) approved by MUSC, which has 
similar features as explained above.   
Data analyses 
To make the analysis more meaningful, participants’ medications were grouped 
under broad categories. According to Ren, Herz, Qian, Smith, and Kazis (2009) and 
Montes et al. (2012), and Granholm et al. (2012), the use of categories of medication 
such as antidepressants and antipsychotics to report participant medication is an 
acceptable technique for conducting research. SPSS version 24 was used for the 
statistical analyses. Descriptive statistics were used to describe and summarize the 
participants’ demographic/clinical data and MAQ data. Chi-Square Test of Independence, 
Point Biserial Correlation, Pearson Correlation and analysis of variance (ANOVA) were 
used to identify any significant differences between participants’ demographic/illness 
data and MAQ data. Ninety-five percent (95%) confidence interval (CI) was used for this 
analysis. 
Correlational analysis and chi-square test were used to identify the relationships between 
the participants: 
• Primary psychiatric diagnoses and medication adherence 
• Duration of primary psychiatric illness and medication adherence 




• Receipt of MPC reminders and medication adherence 
• Multiple diagnoses and medication adherence 
• Number of psychiatric hospitalizations and medication adherence. 
Other relationships explored were the participants: 
• Primary psychiatric diagnosis and MPC method preference 
• Gender and MPC method preference 
• Age and MPC method preference 
• Receipt of MPC reminders and medication adherence.   
• Overall acceptability of MPC (willingness to receive MPC, current use of 






Figure 1. Participants Enrollment  
Sociodemographic information 
Participants’ ages ranged between 18 and 70 (M = 37.7). Gender was 
disproportionately presented in this study with 68.29% (n = 28) being male and 31.71% 
(n = 13) being females. Caucasians represented the majority 60.981% (n = 25) followed 
by African American 31.71% (n = 13). Most of participants 39.2% (n = 16) had some 


















Excluded (n = 35) 
Not meeting inclusion criteria (n = 19) 
• Not on any medications (n = 10) 
• Substance abuse not on 
medications (n = 6) 
• No mental health diagnosis (n = 3)  
Declined to participate (n = 16)  
• Did not want signatures on any 
documents (n = 3) 
• Just not comfortable with research 
(n = 7) 
• No interest in participating (n = 4)  




Assessed for eligibility (n = 76) 
Total Analysed (n = 41) 
Sociodemographic 
information (n = 41) 
Clinical information (n = 
41) 
Medication adherence 
assessment (n = 41) 










Table 1: Frequency for Demographic Information	
Variable	 n	 %	
Gender     
    Female 13 31.71 
    Male 28 68.29 
Age Range     
    18-20 5 12.20 
    21-30 10 24.39 
    31-40 9 21.95 
    41-50 7 17.07 
    51+ 10 24.39 
Ethnicity     
    African American 13 31.71 
    Caucasian 25 60.98 
    Other 3 7.32 
Education     
    Elementary 1 2.44 
    High school 14 34.15 
    Some college/vocational 16 39.02 
    Bachelors 9 21.95 
    Postgraduate 1 2.44 
Note. Due to rounding errors, percentages may not equal 100%.	
Varied sources of income were identified with employment being the major 
source of income reported by 41.46% (n = 17) of participants. Concerning source of 
support after discharge, the majority of participants 85.37% (n = 35) reported having 
family support (M = 0.85, SD = .358). Only 12.0% (n = 5) participants reported receiving 
support from healthcare providers. The majority 80.5% (n = 33) of participants reported 
only one source of support, 17.07% (n = 7) of participants reported 2 sources of support, 
and 2.44% (n = 1) of participants reported support from three sources (family, healthcare 
provider, and friends/coworkers) after discharge. Mobile phone ownership in this 
population was 90.24% (n = 37) with all these mobile phones solely owned by 
participants. When the participants’ willingness to receive reminders to take medications 




some participants who did not own mobile phones yet, wanted reminders. Table 2 below 
gives details about participants’ source of income, support after discharge, mobile phone 
ownership, and willingness to receive reminders to take medications. 
Table 2: Frequency for Sociodemographic Information	
Variable	 n	 %	
Source of support after discharge     
    Family 35 85.37 
    Friends 7 17.07 
    Healthcare 5 12.20 
    Social group 1 2.44 
    Self 1 2.44 
    Missing 0 0.00 
Source of income      
    Employment 17 41.46 
    Social security 8 19.51 
    Family/friends 16 39.02 
    Retirement 2 4.88 
Mobile phone ownership/possession     
    No 4 9.76 
    Yes 37 90.24 
    Sole usage 37 90.24 
    Shared    
Problems taking medications at home     
    No 27 65.85 
    Yes 14 34.15 
Currently receiving reminders 0 0.00 
Would you like reminders     
    No 3 7.32 
    Yes 38 92.68 
Note. Due to rounding errors, percentages may not equal 100%. 
Psychiatric History  
Primary Mental Health Diagnosis 
In examining mental health diagnosis, alcohol/substance use/dependence was the 
primary diagnosis of many of the participants representing 34.15% (n = 14) of the total 
population. Schizophrenia/schizophrenia-like disorders were the minority with 7.32% (n 




primary psychiatric diagnoses. The mean number of primary diagnoses in this population 
was 1.19 (SD = .510). Table 3 below gives the total number of participants with a 
particular primary diagnosis and related characteristics.  
Table 3: Frequency for Primary Psychiatric Diagnosis	
Variable	 n	 %	
Primary diagnosis   
    Alcohol/Substance Use Disorder 14 34.15 
    ADHD 3 7.32 
    Bipolar Disorder 3 7.32 
    Generalized Anxiety Disorder 5 12.20 
    Major Depressive Disorder 12 29.27 
    Schizophrenia/Schizophrenia-Like 2 4.88 
    Other 2 4.88 
Other related characteristics   
  One primary diagnosis  35 85.4 
  Multiple primary diagnoses 6 14.6 
  Two primary diagnosis 4 9.8 
       Three primary diagnosis 2 4.9 
Note. Due to rounding errors, percentages may not equal 100%. 
Comorbidity and Polypharmacy  
 When participants were assessed for other mental health diagnoses, the results 
indicated that, alcohol/substance use/sedative/stimulant/anxiolytic/hypnotic 
abuse/disorder/dependence was the highest 85.37% (n = 35), which is comparable to the 
92.68% (n = 38) of participants’ report of history of substance use. These disorders were 
then followed by generalized anxiety disorder and ADHD/ADD with comparable results 
21.95% (n = 9 each). Table 4 below provides the total number of participants with types 





Table 4: Frequency for Other Psychiatric Diagnosis	
Variable	 n	 %	
Other mental health diagnosis/substance use	  	  	
    Generalized anxiety disorder	 9	 21.95	
    Major depressive disorder	 7	 17.07	
    ADHD	 9	 21.95	
    Bipolar disorder	 5	 12.20	
    Alcohol/substance and other drug abuses	 35	 85.37	
History of substance use 	  	  	
     No	 3	 7.32	
     Yes	 38	 92.68	
Note. Due to rounding errors, percentages may not equal 100%. 
Participants were on various medications to treat mental health issues. The results 
indicate 43.90% (n = 18) participants were on antidepressants, followed by medications 
to treat Opioid/Alcohol dependence 34.15% (n=14). Further, Table 5 below depicts the 
psychiatric medication participants were taking.  
Table 5: Frequency for Psychiatric Medications 	
Variable	 n	 %	
Psychiatric medications	  	  	
    Anticonvulsant	 9	 21.95	
    Antidepressants	 18	 43.90	
    Antipsychotic	 7	 17.07	
    SSRI	 14	 34.15	
    Stimulants	 6	 14.63	
    Opioids Dependence Treatment/Alcohol Relapse Medications	 14	 34.15	
    Gabapentin	 5	 12.20	
    Sedatives	 8	 19.51	
    Other	 5	 12.20	
Note. Due to rounding errors, percentages may not equal 100%.	
Comorbidity was noted when the participants’ primary psychiatric diagnosis and 
other mental health diagnoses were combined. The majority of participants 97.56 (n=40) 
had two or more diagnosis, with most of these participants having two diagnoses (53.66, 
n=22). The mean number of mental health diagnosis in this population was 3.6 (SD = 




managing mental illnesses. Many participants were on two or more medications, with the 
minimum 43.90% (n = 18) on only one psychiatric medications (M =2.80, SD = 1.503). 
Table 6 and 7 provides details on the total number of psychiatric diagnoses and total 
number of psychiatric medications taken by participants. 
Table 6: Frequency for Psychiatric Comorbidity and Polypharmacy	
Variable	 n	 %	
Total number of psychiatric diagnosis	  	  	
    1	 1	 2.44	
    2	 22	 53.66	
    3	 12	 29.27	
    4	 5	 12.20	
    5	 1	 2.44	
Total number of psychiatric medications 	  	  	
    1	 18	 43.90	
    2	 8	 19.51	
    3	 9	 21.95	
    4	 5	 12.20	
    5	 1	 2.44	
Note. Due to rounding errors, percentages may not equal 100%. 
Table 7: Summary Statistics for Psychiatric Comorbidity and Polypharmacy	
Variable	 M	 SD	
Psychiatric diagnosis	 2.59	 0.84	
Number of medications	 2.10	 1.18	
Note. '-' denotes the sample size is too small to calculate statistic.	
Chronicity of Mental Illness 
To ascertain chronicity of mental illness, the duration of the participants’ primary 
psychiatric diagnoses and history of inpatient hospitalizations were examined. The 
duration of the participants’ primary psychiatric diagnosis ranged from less than a year to 
38 years. The majority of participants 51.2% (n = 21) had a primary diagnosis between 0-
5 years. The results indicated (M = 8.36, SD = 8.56) for the duration of primary 




of the population never having been hospitalized. The results indicated (M = 0.88, SD = 
2.14) of psychiatric hospitalization. Table 8 and 9 below provides more details on these 
characteristics.  
Table 8: Frequency for Chronicity of Mental Illness 
Variable n % 
Duration of primary diagnosis in years   
    0-5 21 51.2 
    6-10 9 22 
    11- 15 3 7.3 
    16-20 5 12.2 
    21- 38 2 4.9 
Number of psychiatric hospitalizations     
     0 27 65.85 
     1 9 21.95 
     2 2 4.88 
     4 1 2.44 
      9 1 2.44 
    10 1 2.44 
Note. Due to rounding errors, percentages may not equal 100%. 
Table 9: Summary Statistics for Chronicity of Mental Illness 
Variable M SD 
Duration of primary psychiatric diagnosis in years 8.36 8.56 
Number of psychiatric hospitalizations 0.88 2.14 
Note. '-' denotes the sample size is too small to calculate statistic. 
Physical Health Challenges  
In addition to mental health co-morbidities, participants had physical illnesses. 
Hypertension/cardiac disease was the highest reported by 34.15% (n = 14) of participants, 
reflected in comparable results with anti-hypertensive/cardiac medications taken by 
31.71% (n = 13) of participants. Details on participants’ physical health challenges are 





Table 10: Frequency for Physical Health Challenges and Medications	
Variable	 n	 %	
Medical diagnosis	  	  	
    Hypertension/Cardiac Diseases	 14	 34.15	
    Diabetes	 2	 4.88	
    Asthma	 3	 7.32	
    Hepatitis	 3	 7.32	
    Other	 11	 26.83	
Medical medication	  	  	
    Antihypertensive/Cardiac Medications	 13	 31.71	
    Antidiabetics	 1	 2.44	
    Sedatives	 3	 7.32	
    Anti-Asthmatics 	 3	 7.32	
    Other	 10	 24.39	
Note. Due to rounding errors, percentages may not equal 100%.	
Total Health Challenges  
When participants’ total diagnoses (both medical and psychiatric	comorbidities) 
were comprehensively considered, the total number of psychiatric diagnoses had an 
average of 2.59 (SD = 0.84) and the total number of medical diagnoses had an average of 
0.80 (SD = 0.90) and participants are taking medications for both medical and psychiatric 
conditions. Table 11 provides the details.  
Table 11: Summary Statistics for Total Number of Psychiatric and Medical Diagnoses	
Variable	 M	 SD	
Total Number of Psychiatric Diagnoses	 2.59	 0.84	
Total Number of Medical Diagnoses	 0.80	 0.90	
 
Medication Adherence Assessment  
Results of participants’ medication adherence using the MAQ indicated that 
36.59% (n = 15) of the participants scored one (1), indicating a medium adherence rate. 
Only 19.51% (n = 8) scored Zero (0) on the MAQ, indicating highest medication 




The results indicate the medication adherence rate in this population (M = 1.66, SD = 
1.32). Table 12 and 13 below provides details on participants’ medication adherence 
scores.  
Table 12: Frequency for MAQ Scores	
Variable	 n	 %	
MAQ	  	  	
    0.00	 8	 19.51	
    1.00	 15	 36.59	
    2.00	 6	 14.63	
    3.00	 7	 17.07	
    4.00	 5	 12.20	
Note. Due to rounding errors, percentages may not equal 100%.	




The relationships were determined for medication adherence (using the MAQ) 
and participants demographic/clinical information (gender, ethnicity, mobile phone 
ownership, willingness to receive MPC, primary psychiatric diagnosis, the number of 
medications taken, the number diagnoses, and the number of psychiatric 
hospitalizations). Furthermore, MAQ was the dependent variable.  
For strength of relationship between gender, ethnicity, mobile phone ownership, 
willingness to receive MPC and MAQ, a point biserial correlation, a special case of the 
Pearson correlation aided with determining this relationship. Cohen's standard was used 
to evaluate the strength of the relationship, where coefficients between .10 and .29 
represented a small effect size, coefficients between .30 and .49 represented a moderate 
effect size, and coefficients above .50 indicate a large effect size (Cohen, 1988). The 




observations, allowing comparisons between the two major ethnic groups, Caucasians 
and African Americans. There was a significant negative correlation between Ethnicity 
and MAQ (rpb = -0.53, p < .001). The correlation coefficient between Ethnicity and MAQ 
was -0.53 indicating a large effect size, which suggests that compared to African 
American, Caucasian are associated with a lower MAQ score. Therefore, Caucasians tend 
to have a higher level of medication adherence. However, no relationship was found 
between gender and MAQ (rpb = -0.30, p < .057), mobile phone ownership and MAQ (rpb 
= -0.23, p < .148), and willingness to receive MPC and MAQ (rpb = -0.21, p < .178). 
Table 14 presents the results of the correlation. 
Table 14: Point Biserial Correlations for Demographic Information and MAQ	
Comparison	 n	 rpb	 95% CI	 p	
Gender-MAQ	 41	 -0.30	 [-0.56, 0.01]	 .057	
Ethnicity_-MAQ	 38	 -0.53	 [-0.73, -0.25]	 < .001	
Mobile phone ownership/possession –MAQ	 41	 0.23	 [-0.08, 0.50]	 .148	
Would you like reminders –MAQ	 41	 0.21	 [-0.10, 0.49]	 .178	
Note. The critical values are 0.31, 0.40, and 0.50 for significance levels .05, .01, and .001 
respectively. 
To determine significant differences in MAQ scores and age, ANOVA was 
conducted and showed no relationship existed. Further, descriptive analysis indicated, 
there was better medication adherence in participants aged 51 and above (M = 1.4, SD = 
1.24) than the remaining age group. However, this is at a medium adherence level. Table 
15 shows ANOVA scores and Table 16 provides the details of the descriptive statistics on 
MAQ and age. 
Table 15: Analysis of Variance for MAQ by Age	
Term	 SS	 df	 F	 p	 ηp2	
Age 	 3.16	 4	 0.43	 .785	 0.05	





Table 16: Means, Standard Deviations, and Sample Size for MAQ by Age Range	
Combination	 M	 SD	 n	
18-20	 1.8	 0.84	 5	
21-30	 2	 1.49	 10	
31-40	 1.33	 1.41	 9	
41-50	 1.86	 1.46	 7	
51+	 1.4	 1.26	 10	
Note. - indicate sample size was too small to calculate statistic. 
Also explored were the relationships between medication adherence and the type 
of psychiatric diagnosis, number of psychiatric hospitalizations and duration of primary 
psychiatric diagnosis. MAQ was the dependent variable. 
Descriptive analyses indicate participants with generalized anxiety disorder had 
the best adherence with (M = 0.8, SD = 1.3) yet it was in the medium adherence range 
because the value of the mean was above zero. Moreover, 50% (n = 4) of participants 
diagnosed with generalized anxiety disorder had the highest adherence score (0). 
Participants with bipolar disorder had the least adherence rate (M = 2.67, SD = 1.530) 
indicating a low adherence level. No participant diagnosed with generalized anxiety 
disorder had the highest level of adherence. Table 17 and 10 below provides details about 
participants’ medication adherence and primary psychiatric diagnosis. 
Table 17: Means, Standard Deviations, and Sample Size for MAQ by Primary Diagnosis 	
Combination	 M	 SD	 n	
Alcohol/Substance Abuse	 1.86	 1.35	 14	
ADHD	 1.67	 1.53	 3	
Bipolar Disorder	 2.67	 1.53	 3	
Generalized Anxiety Disorder	 0.8	 1.3	 5	
Major Depressive Disorder	 1.58	 1.31	 12	
Other	 1.5	 1	 4	





Table 18: Frequency for Primary Psychiatric Diagnosis	
Variable 0 1 2 3 4 
Primary Psychiatric Diagnosis           
    Anxiety Disorder 4 (50%) 2 (13%) 0 (0%) 3 (43%) 0 (0%) 
    Major Depressive disorder 2 (25%) 4 (27%) 1 (17%) 0 (0%) 0 (0%) 
    ADHD 4 (50%) 2 (13%) 1 (17%) 1 (14%) 1 (20%) 
    Bipolar disorder 0 (0%) 1 (7%) 1 (17%) 1 (14%) 2 (40%) 
    Alcohol/substance use disorder 7 (88%) 12 (80%) 4 (67%) 7 (100%) 5 (100%) 
Note. Due to rounding errors, column wise percentages may not equal 100. 
An analysis of variance (ANOVA) was conducted to determine whether there 
were significant differences in MAQ based on primary psychiatric diagnosis. 
Schizophrenia was merged into the other category of primary psychiatric diagnosis, since 
there were only 2 participants with Schizophrenia as their primary psychiatric diagnosis. 
The results of the ANOVA were not significant, F (5, 35) = 0.84, p = .527, indicating the 
differences in MAQ among the levels of primary psychiatric diagnosis were all similar 
(Table 19). 
Table 19: Analysis of Variance for MAQ by Primary Psychiatric Diagnosis 
	
Term	 SS	 df	 F	 p	 ηp2	
Primary psychiatric diagnosis	 7.46	 5	 0.84	 .527	 0.11	
Residuals	 61.76	 35	  	  	  	
 
Pearson correlations were conducted between MAQ and participants psychiatric 
history (duration of primary psychiatric diagnosis, number of diagnoses, number of 
medications, and number of hospitalizations) to establish strength of relationship. 
Cohen's standard was used to evaluate the strength of the relationship, where coefficients 




represent a moderate effect size, and coefficients above .50 indicate a large effect size 
(Cohen, 1988).  
There was no significant correlation between MAQ and duration of primary 
psychiatric diagnosis, rp = 0.00, p = 1.00. Therefore, there was no relationship between 
MAQ and duration of primary psychiatric diagnosis. To establish strength of association 
between MAQ and the total number of psychiatric diagnoses, Pearson correlations 
conducted, showed no significant correlation between MAQ and total number of 
psychiatric diagnoses, rp = -0.11, p = .500. This implies that no relationship exists 
between MAQ and total number of psychiatric diagnoses. To find a relationship between 
MAQ and the number of psychiatric medications, Pearson correlations were conducted; 
they showed no significant correlation between MAQ and number of psychiatric 
medications, rp = 0.07, p = .660. Further, the strength of the relationship between MAQ 
and the number of psychiatric hospitalizations examined by Pearson correlation indicated 
that no significant correlation existed between MAQ and number of psychiatric 
hospitalizations, rp = 0.06, p = .730 (Table 26). See Table 20 below for more details. 
Table 20: Pearson Correlation Matrix between MAQ and Participants Psychiatric History	
Variable rp p 
1. MAQ-Duration of Primary Psychiatric Diagnosis 0.00 1.00  
2. MAQ-Total Number of Psychiatric Diagnosis -0.11 .500  
3. MAQ-Number of Psychiatric Medications 0.07 .660  
4. MAQ-Number of Psychiatric Hospitalizations 0.06 .730  
 
However, interesting results were fund when descriptive statistics of medication 
adherence and the duration of primary psychiatric diagnosis, number of diagnoses, 




Descriptive statistics of medication adherence across the number of psychiatric 
diagnosis of participants showed that, the highest medication adherence with participant 
with one psychiatric diagnosis was 2, which is medium adherence level. The highest 
medication adherence level (0) was noted in participants with two or more diagnosis. 
Most participants 15 (36.56%) scored one and two (1 and 2) on the MAQ scale indicating 
medium adherence level. Moreover, participants (n = 5) who had the lowest adherence 
rate also had two or three diagnoses. See Table 21 for the percentages of MAQ across 
diagnosis. 
Table 21: Frequency Table for MAQ and Total Psychiatric Diagnoses 
Variable 0 1 2 3 4 
Total Psychiatric Diagnoses           
    1 0 (0%) 0 (0%) 1 (17%) 0 (0%) 0 (0%) 
    2 2 (25%) 11 (73%) 4 (67%) 3 (43%) 2 (40%) 
    3 4 (50%) 2 (13%) 0 (0%) 3 (43%) 3 (60%) 
    4 1 (12%) 2 (13%) 1 (17%) 1 (14%) 0 (0%) 
    5 1 (12%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Note. Due to rounding errors, column wise percentages may not equal 100 
 
Descriptive statistics showed that, the levels of MAQ was spread across the 
different types of psychiatric medications taken. Fifty percent of participants (50%, n=4) 
on antipsychotic medications had highest level of adherence (0). Table 22 shows 





Table 22: Frequency for Psychiatric Medications	
Variable 0 1 2 3 4 
Psychiatric medications           
    Anticonvulsant 2 (25%) 3 (20%) 1 (17%) 1 (14%) 2 (40%) 
    Antidepressants 2 (25%) 6 (40%) 3 (50%) 4 (57%) 3 (60%) 
    Antipsychotic  4 (50%) 1 (7%) 0 (0%) 1 (14%) 1 (20%) 
    SSRI 3 (38%) 7 (47%) 2 (33%) 1 (14%) 1 (20%) 
    Stimulants 3 (38%) 1 (7%) 0 (0%) 2 (29%) 0 (0%) 
    Opioids/alcohol medications 2 (25%) 5 (33%) 1 (17%) 4 (57%) 2 (40%) 
    Gabapentin 1 (12%) 1 (7%) 1 (17%) 2 (29%) 0 (0%) 
    Sedatives 1 (12%) 1 (7%) 1 (17%) 5 (71%) 0 (0%) 
    Other 1 (12%) 2 (13%) 1 (17%) 0 (0%) 1 (20%) 
Note. Due to rounding errors, column wise percentages may not equal 100%. 
Moreover, descriptive statistics showed that, the highest medication adherence 
reported in participants was 38% (n=3) among those taking only one medication with 
Zero (0) score on the MAQ. Similarly, highest medication adherence was noted in 12.5% 
(n = 1) participant who was on two medications, 25% (n = 2) on three medications and 
25% (n=2) on four medications. The highest mediation adherence in participants on five 
(5) medications was 3 indicating low medication adherence. Table 23 provides the details 
of these results.  
Table 23: Frequency for MAQ and Number of Psychiatric Medications 
Variable 0 1 2 3 4 
Number of Psychiatric Medications           
    1 3 (38%) 9 (60%) 3 (50%) 2 (29%) 1 (20%) 
    2 1 (12%) 2 (13%) 2 (33%) 0 (0%) 3 (60%) 
    3 2 (25%) 2 (13%) 1 (17%) 3 (43%) 1 (20%) 
    4 2 (25%) 2 (13%) 0 (0%) 1 (14%) 0 (0%) 
    5 0 (0%) 0 (0%) 0 (0%) 1 (14%) 0 (0%) 
Note. Due to rounding errors, column wise percentages may not equal 100%. 
 
However, descriptive statistics shows that participants with 0-2 number of 




two hospitalizations. For duration of primary psychiatric diagnosis, medication adherence 
scores varied. Table 24 gives details of this results. 
Table 24: Frequency for MAQ and Duration of Primary Psychiatric Diagnosis and 
Number of  Psychiatric Hospitalization 
Variable 0 1 2 3 4 
Duration of primary psychiatric diagnosis 
in years            
    0-5 3(36%) 6 (45%) 4 (68%) 4 (57%) 2 (40%) 
    6-10 2(24%) 4 (27%) 1 (17%) 1 (14%) 1 (20%) 
    11- 15 0 (0%) 0 (0%) 1 (17%) 1 (14%) 1 (20%) 
    16-20 2 (25%) 3 (21%) 0 (0%) 0 (0%) 0 (0%) 
    21- 38  1 (12%) 0 (0%) 0 (0%) 1 (14%) 1 (20%) 
Number of psychiatric hospitalization           
    0 5 (62%) 10 (67%) 5 (83%) 4 (57%) 3 (60%) 
    1 1 (12%) 4 (27%) 1 (17%) 1 (14%) 2 (40%) 
    2 2 (25%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
    4 0 (0%) 0 (0%) 0 (0%) 1 (14%) 0 (0%) 
    9 0 (0%) 0 (0%) 0 (0%) 1 (14%) 0 (0%) 
    10 0 (0%) 1 (7%) 0 (0%) 0 (0%) 0 (0%) 
Note. Due to rounding errors, column wise percentages may not equal 100%. 
Assessment of MPC  
Perceived advantages and disadvantages of receiving MPC as a supportive intervention 
for medication adherence. 
The ability to remember to take medications is reported to be the main reason 
participants want MPC as a supportive intervention for medication adherence, as 92.68% 
(n = 38) of participants chose that reason. Being dependent on reminders and not 
remembering to take medications if the phone turns off or is destroyed as well as not 
getting the reminders at all were noted by 46.34% (n = 19) of the participants as a 





Table 25: Frequency for Perceived Advantages and Disadvantages of Receiving MPC	
Variable	 n	 %	
Perceived Advantages/Benefits 	 	 	
Able to remember to take medications.	 38	 92.68	
Able to receive advice if cannot remember details about      my 
medications.	 28
	 68.29	
Able to ask questions about treatment.	 22	 53.66	
Able stay on medications and not just stop taking them.	 25	 60.98	
Will know someone cares about him/her.	 18	 43.90	
Will be more responsible since will constantly be reminded to 
take medications	 27
	 65.85	
Will not have to worry about tracking the time to take     
medications	 22
	 53.66	
It will save time 14	 34.15	
Perceived Disadvantages/Problems	 	 	
It will distract me.	 7	 17.07	
Will feel controlled 6	 14.63	
Will not have any privacy 5	 12.20	
Will cause people around to know I take medications 4	 9.76	
Will be dependent on reminders and not remember to take 
medications if phone turns off, gets destroyed or if I do not get 
the reminders          
19	 46.34	
 
MPC Method Preference  
The preferred method of MPC was TM (n = 29, 70.73%). Moreover, PC was 
noted to be the least preferred method by the majority 56.10% (n=23) of participants but 
was chosen by 39.02% (n=16) as a second choice. TMPC was also chosen by 41.46% 
(n=17) as second choice, which is comparable to the number of participants who chose 





Table 26: Frequency for MPC Choices	
Variable n % 
Preference     
    TM  29 70.73 
    PC  3 7.32 
    TMPC  9 21.95 
Second choice     
    TM  8 19.51 
    PC  16 39.02 
    TMPC  17 41.46 
Third choice     
    TM  3 7.32 
    PC  23 56.10 
    TMPC  15 36.59 
Note. Due to rounding errors, percentages may not equal 100%.  
Reasons for a preferred MPC method  
Convenience was the main reason for participants (n = 25, 68.29%) choosing TM 
as a preferred MPC method.  Similarly, convenience and simple to use were the two 
major reasons participants chose TMPC as a second preferred method (n = 6, 14.63 and n 
= 6, 14.63). However, 41.46% (n = 17) of participants chose PC as third choice for being 
more distracting. Tables 27, 28, and 29 gives details about participants’ MPC choices, 
reasons for choices, and p-values obtained. 
Table 27: Frequency for MPC Method Chosen as Preferred/First Choice 	
Variable	 n	 %	
TM reason     
     Convenience 28 68.29 
     Simple to use 24 58.54 
     Less distractive 22 53.66 
     Requires less time. 22 53.66 
     Provide privacy 11 26.83 
     Receive advice 13 31.71 
     Get someone to talk to about medications 5 12.20 





PC reasons   
     Convenience 3 7.32 
     Simple to use 3 7.32 
     Less distractive 0 0.00 
     Requires less time. 1 2.44 
     Provide privacy 2 4.88 
     Receive advice 3 7.32 
     Get someone to talk to about medications 2 4.88 
     Get someone to talk to about symptoms 2 4.88 
TMPC reasons   
     Convenience 6 14.63 
     Simple to use 6 14.63 
     Less distractive 2 4.88 
     Requires less time. 3 7.32 
     Provide privacy 3 7.32 
     Receive advice 6 14.63 
     Get someone to talk to about medications 5 12.20 
     Get someone to talk to about symptoms 6 14.63 
Note. Due to rounding errors, percentages may not equal 100%. 
Table 28: Frequency for MPC Method Chosen as Second Choice 	
Variable	 n	 %	
TM reason   
     Convenience 6 14.63 
     Simple to use 5 12.20 
     Less distractive 4 9.76 
     Requires less time. 5 12.20 
     Provide privacy 6 14.63 
     Receive advice 3 7.32 
     Get someone to talk to about medications 1 2.44 
     Get someone to talk to about symptoms 2 4.88 
PC reasons   
     Convenience 6 14.63 
     Simple to use 7 17.07 
     Less distractive 2 4.88 
     Requires less time. 1 2.44 
     Provide privacy 4 9.76 
     Receive advice 11 26.83 
     Get someone to talk to about medications 9 21.95 
     Get someone to talk to about symptoms 8 19.51 
TMPC reasons   
     Convenience 10 24.39 





     Less distractive 6 14.63 
     Requires less time. 4 9.76 
     Provide privacy 9 21.95 
     Receive advice 4 9.76 
     Get someone to talk to about medications 8 19.51 
     Get someone to talk to about symptoms 10 24.39 
Note. Due to rounding errors, percentages may not equal 100%.	
Table 29: Frequency for MPC Method Chosen as Third Choice 	
Variable	 n	 %	
TM reason for being third     
    Less Convenience 1 2.44 
    Not Simple to use 1 2.44 
    More distractive 1 2.44 
    Requires more time. 0 0.00 
    Provides less privacy 1 2.44 
    Cannot Receive advice 3 7.32 
    Cannot Get someone to talk to about medications 3 7.32 
    Cannot Get someone to talk to about symptoms 3 7.32 
PC reasons     
    Less Convenience 12 29.27 
    Not Simple to use 2 4.88 
    More distractive 17 41.46 
    Requires more time. 11 26.83 
    Provides less privacy 9 21.95 
    Cannot Receive advice 2 4.88 
    Cannot Get someone to talk to about medications 0 0.00 
    Cannot Get someone to talk to about symptoms 0 0.00 
TMPC reasons     
    Less Convenience 3 7.32 
    Not Simple to use 1 2.44 
    More distractive 10 24.39 
    Requires more time. 9 21.95 
    Provides less privacy 6 14.63 
    Cannot Receive advice 0 0.00 
    Cannot Get someone to talk to about medications 0 0.00 
    Cannot Get someone to talk to about symptoms 0 0.00 
Note. Due to rounding errors, percentages may not equal 100%. 
Conducting a Chi-Square Test of Independence aided with examining the 




and TMPC). There was significant between Preference and convenience ( χ2(2) = 28.30, p 
< .001); Preference and simple to use (χ2(2) = 17.73, p < .001); preference and 
destruction (χ2(2) = 14.13, p < .001); preference and less time (χ2(2) = 14.13, p < .001); 
preference and receiving advice (χ2(2) = 24.99, p < .001); and preference and talking 
about medications (χ2(2) = 20.25, p < .001). However, there was non-significant 
relationship between preference getting more privacy χ2(2) and talking about symptoms 
(χ2(2) = 3.10, p = .212 and χ2(2) = 0.35, p = .838 respectively). Table 30 and 31 gives the 
observed and expected frequencies for relationship between the type of MPC preferred 
and reasons given for choice made. 
Table 30: Frequencies for Reasons for MPC Method Preferred  
  Convenience Simple to Use Less Distractive Requires Less Time 
Preference 0 1 0 1 0 1 0 1 
PC  3[0.95] 0[2.05] 3[1.24] 0[1.76] 3[1.39] 0[1.61] 3[1.39] 0[1.61] 
TMPC  8[2.85] 1[6.15] 8[3.73] 1[5.27] 8[4.17] 1[4.83] 8[4.17] 1[4.83] 
TM  2[9.20] 27[19.80] 6[12.02] 23[16.98] 8[13.44] 21[15.56] 8[13.44] 21[15.56] 
Note. Values formatted as Observed[Expected]. 
Table 31: Frequencies	for Reasons for MPC Method Preferred 
  Receive advice Talk About Medications 




 1 0 1 0 1 0 1 
PC  3[2.56] 0[0.44] 3[2.63] 0[0.37] 3[2.20] 0[0.80] 3[2.71] 0[0.29] 
TMPC  3[7.68] 6[1.32] 4[7.90] 5[1.10] 8[6.59] 1[2.41] 8[8.12] 1[0.88] 
TM  29[24.76] 0[4.24] 29[25.46] 0[3.54] 19[21.22] 10[7.78] 26[26.17] 3[2.83] 
Note. Values formatted as Observed [Expected] 
Relationship or differences between MPC Preference and Demographic/Clinical 
Information 
Interesting results were found when the relationship between participants’ MPC 




adherence, medication adherence, and MHS users’ overall acceptance of MPC as a 
method of providing support to increase medication adherence after discharge. MPC 
preference was the dependent variable. 
Frequencies and percentages were calculated for MPC preference split by primary 
psychiatric diagnosis. For alcohol/substance abuse (n = 9, 64%), ADHD (n = 2, 67%), 
bipolar disorder (n = 3, 100%), generalized anxiety (n = 5, 100%), major depressive 
disorder (n = 8, 67%), and other psychiatric diagnoses (n = 2, 100%), the preferred 
method was TM. For schizophrenia, the preferred method was TMPC (n = 2, 100%). 
Frequencies and percentages are presented in Table 32. 












    PC	 1 (7%)	 1 (33%)	 0 (0%)	 0 (0%)	 1 (8%)	 0 (0%)	 0 (0%)	
    TMPC 	 4 (29%)	 0 (0%)	 0 (0%)	 0 (0%)	 3 (25%)	 2 (100%)	 0 (0%)	
    TM 	 9 (64%)	 2 (67%)	 3 (100%)	 5 (100%)	 8 (67%)	 0 (0%)	 2 (100%)	
Note. Due to rounding errors, column wise percentages may not equal 100%. 
Chi-Square Tests of Independence were conducted to examine whether MPC had 
a relationship with gender or age. There were 2 levels in Gender: Female and Male. 
There were 5 levels in Age: 18-20, 21-30, 31-40, 41-50, and 51+. There were 3 levels in 
MPC Preference: PC, TMPC, and TM.	Prior to conducting the analysis, the assumption 
of adequate cell size was assessed, which requires all cells to have expected values 
greater than one, and 80% of cells to have expected values of at least five (McHugh, 
2013).	
For gender the expected value (in square brackets), females who chose PC as their 




values for each cell were greater than 5 as seen in Table 26. These violate the 
assumptions of the Chi-Square Test for Independence, so the results are to be interpreted 
with caution. The results of the Chi-Square test were not significant, χ2(2) = 2.07, p = 
.355, suggesting that Gender and MPC preference are not related to one another. This 
implies that the observed frequencies were not significantly different than the expected 
frequencies. Table 33 presents the results of the test.	
Table 33: Frequencies for Gender and MPC	
 	 MPC	
Gender	 PC 	 TMPC 	 TM 	
Female	 0[0.95]	 4[2.85]	 9[9.20]	
Male	 3[2.05]	 5[6.15]	 20[19.80]	
Note. Values formatted as Observed[Expected]. 
In examining the relationship between age and MPC preference, some of the cells 
had expected values less than 1, and only 20% (less than 80%) of the cells had expected 
frequencies of at least 5 as shown in Table 4.  These violate the assumptions of the Chi-
Square Test for Independence, so the results must be interpreted with caution.  The 
results of the Chi-Square test were not significant, χ2(8) = 6.15, p = .631, suggesting that 
Age and MPC preference are not related to one another. This implies that the observed 
frequencies were not significantly different than the expected frequencies. Table 34 
presents the results. 
Table 34: Frequencies for Age and MPC	
 	 MPC	
Age	 PC	 TMPC	 TM	
18-20	 1[0.37]	 2[1.10]	 2[3.54]	
21-30	 1[0.73]	 1[2.20]	 8[7.07]	
31-40	 0[0.66]	 1[1.98]	 8[6.37]	
41-50	 0[0.51]	 2[1.54]	 5[4.95]	
51+	 1[0.73]	 3[2.20]	 6[7.07]	




A Chi-Square Test of Independence was conducted to examine whether MPC 
preference and Ethnicity were independent. There were 3 levels in MPC preference: PC, 
TMPC, and TM. There were 3 levels in Ethnicity: Other, African American, and 
Caucasian.	Prior to conducting the analysis, the assumption of adequate cell size was 
assessed, which requires all cells to have expected values greater than zero, and 80% of 
cells to have expected values of at least five (McHugh, 2013). A total of 3 cells had 
expected frequencies less than 1, indicating the first condition was violated. A total of 
only 33.33% (less than 80%) of the cells had expected frequencies of at least five, 
indicating the second condition was not met. Thus, the results should be interpreted with 
caution. The results of the Chi-Square test were significant, χ2(4) = 13.99, p = .007, 
suggesting that MPC preference and Ethnicity are related to one another. The following 
level combinations observed values that were greater than the expected values: PC: other, 
PC: African American, TMPC: African American, and TM: Caucasian. The following 
level combinations observed values that were less than the expected values: TMPC: 
other, TM: other, TM: African American, PC: Caucasian and TMPC: Caucasian. Table 
35 presents the results of the Chi-Square test. 
Table 35: Frequencies for MPC and Ethnicity	
 	 Ethnicity	
MPC	 African American	 Caucasian	 Other	
PC	 2[0.95]	 0[1.83]	 1[0.22]	
TMPC	 6[2.85]	 3[5.49]	 0[0.66]	
TM	 5[9.20]	 22[17.68]	 2[2.12]	
Note. Values formatted as Observed[Expected]. 
To examine whether MAQ and Preference were independent, a Chi-Square Test 
of Independence was conducted. The results were not significant, χ2(8) = 9.64, p = .292, 




that the observed frequencies were not significantly different than the expected 
frequencies. Table 36 presents the results of the Chi-Square test. 
Table 36: Frequencies for MPC Preference and MAQ	
 	 Preference	
MAQ	 PC preference	 TMPC preference	 TM preference	
0	 0[0.59]	 1[1.76]	 7[5.66]	
1	 0[1.10]	 3[3.29]	 12[10.61]	
2	 1[0.44]	 2[1.32]	 3[4.24]	
3	 2[0.51]	 2[1.54]	 3[4.95]	
4	 0[0.37]	 1[1.10]	 4[3.54]	
Values formatted as Observed[Expected].	
Overall acceptability Assessment 
Lastly, the MHS users’ overall acceptability of MPC was examined, and the 
association between medication adherence and mobile phone ownership as well as liking 
reminders were assessed. 
Problems Foreseen When Receiving MPC Intervention and Solution  
Problems participants anticipated with receiving MPC varied and included (a) the 
inability to receive the message/call due to network issues, (b) mobile phone battery 
running down, (c) distraction, and (d) inability to retrieve messages. Table 37 gives 
details about this information. 
Table 37: Frequency Table for Problems Foreseen with MPC	
Variable N % 
Problems participants foreseen   
Inability to read and write in English.  2 4.88 
Not be able to understand the message I receive. 5 12.20 
Not receiving the message/call due to network issues   24 58.54 
Not able to retrieve message/text.  10 24.39 
May not be able to read text message if the letter 
characters are too small. 
4 9.76 
Lack of skills using mobile phone for the purpose of 




Variable N % 
Feeling discomfort with typing response. 2 4.88 
Inability to pay for the extra charge for receiving mobile 
phone contact.  
5 12.20 
Mobile phone battery may run down. 15 36.59 
Distractions 12 29.27 
 
With regards to overcoming the problems with receiving MPC intervention, 
70.7% (n = 29) mentioned that the MPC message should be clear, simple and 
understandable. Additionally, MPC should be simple, clear and understandable, receiving 
MPC in an understood language, receiving MPC at preferred times, and ensuring that the 
mobile phone is charged were also chosen by participants 70.73 (n = 29), 39.02% (n = 
16), 36.59 (n = 15), and 34.15% (n = 14), respectively. Other reasons given were 
comparable. Table 38 below provides details about problems foreseen as well as 
solutions to problems related to receiving the MPC intervention. 
Table 38	
Frequency Table for Overcoming the Problems	
Variable	 n	 %	
How to overcome these problems   
Prefer to receive text and phone calls in the language understood 16	 39.02	
Prefer the message be sent to caregiver if cannot read and write 1	 2.44	
The messages should be clear, simple and understandable. 29	 70.73	
Use soft key options for responding to mobile phone contacts. 7	 17.07	
Use on-screen number options for responding to mobile phone 
contacts. 12
	 29.27	
Receiving demonstration on how to retrieve the text message/calls 4	 9.76	
Making sure phone bills are paid to get network all the time 12	 29.27	
The letters of the text message should be in big sizes for me to read 
easily. 6
	 14.63	
Prefer to receive phone calls options due to discomfort with typing 4	 9.76	
Prefer to receive prepaid mobile phone contact 8	 19.51	
Want to receive the mobile phone contact based on preferred times  15	 36.59	
Ensuring mobile phone is charged at all times. 14	 34.15	




Concerning mobile phone ownership, 90.2% (n = 37) of participants owned a 
mobile phone, but no one (0%) was currently receiving MPC reminders to take 
medications. However, 92.2% of participants wanted to receive MPC reminders.	Given 
that no participants responded that they currently receive reminders, this variable was not 
included in the chi-square analysis.	Most participants, 92% (n = 34), both owed mobile 
phones and wanted reminders, while 8% (n = 3) of participants who owned mobile phone 
did not want reminders, and 9.76% (n=4) of participants who did not have mobile phones 
wanted reminders.	Table 39 depicts this information. 
Table 39: Frequency Table for Mobile Phone Ownership and Liking Reminders	
Variable	 No	 Yes	
Would you like reminders	  	  	
    No	 0 (0%)	 3 (8%)	
    Yes	 4 (9.76%)	 34 (92%)	
Note. Due to rounding errors, column wise percentages may not equal 100%.	
Conducting a point biserial correlation analysis for MAQ aiding with examining 
if the participants liked reminders and mobile phone ownership. A point biserial 
correlation is a special case of the Pearson correlation. Cohen's standard was used to 
evaluate the strength of the relationship, where coefficients between .10 and .29 represent 
a small effect size, coefficients between .30 and .49 represent a moderate effect size, and 
coefficients above .50 indicate a large effect size (Cohen, 1988). There was no significant 
correlation between MAQ and liking reminders, rpb = 0.21, p = .178.  This suggests that 
no relationship exists between MAQ and liking reminders. For relationship between 
MAQ and mobile phone ownership, there was no significant correlation between MAQ 




relationship between MAQ and mobile phone ownership. Table 40 presents the results of 
the correlation. 
Table 40: Point Biserial Correlations for Liking Reminders,	Mobile Phone Ownership 
and MAQ	
Comparison	 n	 rpb	 95% CI	 p	
MAQ-Liking Reminders	 41	 0.21	 [-0.10, 0.49]	 .178	
MAQ-Mobile Phone Ownership 41 0.23 [-0.08, 0.50] .148 
 
Discussion 
The results of this study revealed some interesting findings about MPC 
preferences in mental health service users. The results suggest that mobile phone 
ownership (90.2%) is common in this population, similar to findings from other studies 
(Ennis et al., 2012; Miller et al., 2015) and comparable to the national average as noted 
by Campbell et al., (2015). However, the result of the study suggests the need for 
clinicians to provide patients who do not own mobile phones with mobile phones when 
considering incorporating MPC into routine clinical care to enhance medication 
adherence in all mental health service users. Furthermore, the need for reminders to take 
medications cannot be overestimated and seems to be an expectation when ensuring 
medication adherence in this population, taking into account that 92.2% of the 
participants expressed interest in such reminders. Comparatively, 90.2% of participants 
owned a mobile phone and 92.7% of the participants’ expressed interest in receiving 
reminders, which suggests that even though some participants did not own mobile 
phones, they still wanted reminders. The results suggest the need for reminders in this 
population an expectation that should not be underestimated by mental health 




Moreover, there is reason for concern due to participants’ medication adherence 
scores on the MAQ, 51.2% having medium adherence (1 and 2), 29.3% having low 
adherence to medications ratings (3-4), and only 19.5% having the highest medication 
adherence rate (0). It is important to note that participants with medium and low 
medications adherence rates are the majority (80.5%), which may explain why 92.7% of 
the participants expressed interest in receiving reminders to take medications. Suggesting 
that some participants with the highest medication adherence rating and those who did 
not own mobile phones still wanted reminders to take medications. The medication 
adherence rate in this population is (M = 1.66), suggesting medium adherence according 
to the MAQ scores, confirming the continued challenge in medication adherence in this 
population as evidenced in mental health research (Tomko et al., 2013).  
Medication adherence was also compared with the participants’ 
demographic/clinical information, and interesting results were found. It was noted that 
the type of primary psychiatric diagnosis had no relationship with medication adherence 
(p = .527), nor did the total number of primary psychiatric diagnoses (p = .500), nor did 
the duration of primary psychiatric diagnosis (p = 1.00). Even though a non-significant 
relationship was found between MAQ and primary psychiatric diagnosis (p = .527) of 
participants, a closer look at individual numbers of diagnosis, and medication gave us 
some idea about trends in medication adherence in this population. Of the total 
population, the eight participants with the highest medication adherence (MAQ = 0) had 
only one psychiatric diagnosis. However, the five participants who had the lowest 




Similarly, no significant relationship (p = .660) was found with medication 
adherence and number of medications taken. However, for trends in adherence, four 
participants forming 50% of participants with the highest adherence rate (MAQ = 0) were 
on only one medication. Moreover, no participants taking five medications had the lowest 
adherence rating. Likewise, no significance was found between medication adherence 
and the number of psychiatric hospitalization (p = .730). The variation in medication 
adherence scores across the numbers and types of psychiatric diagnosis or medications 
indicate that — although no statistically significant difference existed in medication 
adherence, type/number of diagnosis, and type/number of medications taken — 
descriptive statistics of individual trends in the type and number of medications taken 
suggest otherwise, indicating the need for further studies to confirm study results. 
Participants’ medication adherence was significant for ethnicity (p < .001). 
Caucasians were noted to have low MAQ scores compared to African Americans and 
other ethnicities. Also, the non-significance noted in participants MAQ scores and 
participants mobile phone ownership and liking reminders should be looked at closely (p 
= .148, p = .178 respectively). The results suggest that mental health providers should not 
assume that any of these factors could increase or decrease medication adherence in this 
population when applying an intervention to increase medication adherence.  
Reasons for or not wanting reminders  
Even though non-significant results were noted for most of the participants’ 
medication adherence and demographic/clinical data when compared, it is important to 
remember that, 80.5% participants who fell below the highest medication adherence 




expressed knowledge about the benefits of receiving reminders to take medications. 
Among these benefits, at least 50% of participants expressed remembering to take my 
medications, receiving advice about details of medications, ability to ask questions about 
treatment, ability to stay on medications and not just stop taking it, knowing someone 
cares, being more responsible because of constant reminders to take medications, and not 
worrying about tracking the time to take medications confirming participants’ awareness 
of the benefits MPC could bring to mental health treatment (Palmer-Claus et al., 2013).  
Furthermore, the results indicated that participants are aware of the four types of 
social support MPC might provide as each of these benefits falls under a social support 
category (instruments [remembering to take medications due to constant reminders], 
informational [receiving advice and asking questions about treatment], emotional 
[knowing someone cares; not worrying about tracking the time], and valuation [being 
more responsible]). The results also confirmed the potential importance of continuous 
support to ensure continuous long-term treatment with close monitoring (Ainsworth et 
al., 2013; Bright, 2018; Palmier-Claus et al., 2013). The 92.7% expressing that 
remembering to take medications was the benefit of MPC confirms that participants are 
aware of the benefits MPC brings to mental health care as noted in similar study 
(Granholm et al., 2012).   
However, participants also noted that receiving MPC is not without some sort of 
risk. The disadvantages participants expressed about receiving MPC included distraction, 
feeling controlled, lack of privacy, causing people around to know participants are taking 
medications, being dependent on reminders, and not remembering to take medications if 




privacy, distraction, and feelings of being controlled can be reduced or avoided if 
participants can choose preferred times to take medication as noted in similar studies 
(Beebe et al., 2008; Beebe et al., 2014; Montes et al., 2012). The disadvantages expressed 
by participants about receiving MPC demonstrates that autonomy is important in every 
treatment intervention which aligns with the social support theory (Glanz et al., 2008).  
Identification of preferences  
After participants expressed value in receiving MPC, preferences for a MPC 
method was assessed. The results indicate 70.7% of participants preferred the TM 
method. However, in similar study that did not indicate participants MPC method 
preference, showed increases in medication adherence in participants receiving TMPC 
when compared to TM and PC (Beebe et al., 2014).	This study therefore seeks to inform 
clinicians that even though a high medication adherence rate was noted in participants 
receiving TMPC in Beebe et al., (2014) study, TMPC might not be a preferred method. 
Moreover, research has shown that, when patients do not receive the preferred treatment 
method, the decision not to initiate or complete treatment could be associated with 
disappointment or dissatisfaction with the treatment offered by the clinician (Raue et al., 
2009). Hence, taking patients’ preferences into consideration when applying MPC may 
be important to increasing medication adherence in this population because reduction in 
adhering to TMPC could have occurred with time.  
In prospective, MPC trial taking into account participant preferences would add to 
the knowledge of whether patient preference with MPC would enhance medication 





Reasons for choosing preferred MPC method 
Participants’ reasons for choosing a preferred MPC method was evaluated, and 
results showed that 70.7% of the participants were aware that TM is convenient, simple 
to use, less distractive and requires less time compared to PC and TMPC. The 
relationship between participants’ reasons for choosing a MPC method as preferred was 
highly significant (p < .001) for convenience, simple to use, less distractive, required less 
time, receiving advice, and talking about medications. 
However, 29.3% of participants saw PC as less convenient, 41.5% saw PC as 
more distractive and 26.8% saw PC as more time consuming, which could explain why 
only 7.32% (n = 3) chose PC as a preferred method.  
Relationship between MPC method preference and participants’ characteristics 
In exploring participants’ preferred MPC method and demographic/clinical data, 
interesting results were found. There was no relationship between MPC preference and 
age (p = .631) even though the age ranged from 18-70 years. Non-significant relationship 
(p = .355) was also found for gender and MPC preference. However, preference was 
significant with ethnicity (p = .007). African Americans preferred TMPC (2.85%) while 
Caucasians preferred TM (17.68%) suggesting that providers should consider ethnicity of 
participants when applying the MPC intervention. However, because PC and TMPC were 
combined into one group, the results of this study did not clearly indicate which of the 
two methods (PC or TMPC) was most preferred by African Americans. 
Considering psychiatric diagnoses, participants preferred TM, except all those 
(100%) diagnosed with schizophrenia, who preferred TMPC confirming Beebe et al.’s 




when applying MPC in treatment of patients with schizophrenia. Another interesting 
finding was participants diagnosed with ADHD did not want TMPC. The reason for this 
result should be investigated in future studies. Further, mixed results were found for all 
three MPC preferences with participants diagnosed with major depressive disorder and 
alcohol/substance use disorder/dependence. However, these results cannot be generalized 
in this population due to the small sample size. There is therefore a need for further 
studies with larger sample sizes to produce generalizable results and to identify any 
statistical significance.  
When participants MPC preference was compared to medication adherence 
scores, non-significant differences were found (p =.292), suggesting that MPC preference 
and medications adherence are independent. However, this non-significant relationship 
between medication adherence and MPC is not conclusive since this is not an 
intervention study and does not predict a relationship between MPC preference and 
medication adherence. Furthermore, subjective measures were used to assess medication 
adherence in this population (self-report) which was noted to be unreliable and 
susceptible to social desirability and memory biases causing overestimate in medication 
regimens. The disadvantages of using a subjective measure in this study suggest the need 
for an intervention study and the use of objective medication adherence measures such as 
pill count and plasma levels. The use of objective measures in medication adherence 







Finally, the participants’ impression of receiving MPC was evaluated by assessing 
the overall acceptability of MPC, which included MPC preference, mobile phone 
ownership, willingness to receive reminders, problems foreseen with MPC, and solutions 
for these problems. A network issue was one major concern of participants when 
receiving MPC intervention. Further, the numerous solutions participants reported for 
overcoming problems arising from receiving MPC intervention included receiving MPC 
in language understood, clarity, simplicity and understandability of MPC intervention. 
Receiving MPC at preferred times, prepaid contacts and use of soft key should be 
strongly considered	for successfully implementing MPC intervention. Differences in 
language are noted to be one of the barriers to effective communication (Schyve, 2007). 
Therefore, ensuring MPC is done in language patients understand is important for MPC 
to be effective in this population. Additionally, paying for extra charges with MPC will 
be a challenge in this population, considering that 58.5% of participants depend on social 
security/disability funds, retirement funds, or family and friends with 39.0% of income 
from family and friends. One solution to problems with receiving MPC was making sure 
phone bills are paid to maintain service all the time, which implies that if MPC is to be 
included in standard of care, bill assistance and financial guidance should be considered. 
Moreover, the non-significant relationship identified between medication 
adherence and mobile phone ownership as well as liking reminders (p = .148 and p = 
.178 respectively) should be further explored further through an intervention study to 





Limitations and Recommendations  
This study has several limitations. The first limitation is results of this study are 
not generalizable given its small sample size, and there is consequently a need for 
replication in a larger population. The second limitation is to accurately predict a 
relationship between MPC method preference and participants’ demographic/clinical 
information as used in this study. There is a need for an intervention study to compare 
participants who had the opportunity to choose a preferred MPC method and those who 
did not. The third limitation is an intervention study is needed to establish a relationship 
between medication adherence and MPC preferences. Finally, a follow up study of 
participants from an inpatient psychiatric setting to an outpatient setting should be done 
to identify relationships based on the time of application of the MPC intervention.  
Conclusion 
This study reported information about MPC preferences to enhance medication 
adherence after discharge for mental health service users. Providers should not 
underestimate the need for reminders to take medications in this population, considering 
that the majority of participants fell within the moderate to low medication adherence 
ratings. Further, participants’ willingness for MPC reminders to take medications 
confirms a struggle with medication adherence and the need for mental health providers 
to continue support even after discharge to increase medication adherence.  
The need to identify preferences in MPC method should be a priority when 
providers apply an MPC intervention to increase medication adherence. Based on the 
results, providers should not overlook the participants’ expressions of autonomy by 




Similarly, participants preferred time for applying MPC intervention is likely to reduce 
lack of privacy, distraction, and feelings of being controlled expressed by participants. It 
is important to note that in this study, MPC was significant for relationship with ethnicity 
and preferences although not significant statistically with diagnosis or number of 
medications. In conclusion, identifying MPC preference in mental health service users is 
as essential as applying the MPC intervention itself in increasing medication adherence 
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Summary and Conclusion 
This dissertation contains two integrative reviews and a descriptive correlational 
study. The first review is on the validity and reliability of instruments used to measure 
medication adherence in patients with schizophrenia. The second integrative review 
reports on the use of mobile phone contact to increase medication adherence in patients 
with severe mental illness. The descriptive correlational study identifies the mobile phone 
contact method preferred by individuals to increase medication adherence after discharge.  
Results from the three studies shed new light on   medication adherence in 
individuals with mental illness. Information presented from the first manuscript showed 
that available measurement instruments, while still relevant for measuring medication 
adherence, are limited; new measures are needed because all available instruments lack 
either validity, reliability, or sensitivity, and a gold standard for measuring medication 
adherence in patients has yet to be established. The second manuscript provides 
information on the use of mobile phone contact to support increased medication 
adherence in patients with severe mental illness.  Results indicate that some promising 
data are emerging on mobile phone contact use to increase medication adherence in 
individuals with severe mental but limited data exist on its use. Hence, there is a need for 
more studies to produce conclusive results.  
The third manuscript, a descriptive correlational study, provides information on 
mobile phone contact method preferences among mental health service users for 
supporting increased medication adherence after discharge. The results from the study 
indicate that reminders are essential to ensure medication adherence, as demonstrated by 




adherence in this population was a mean of 1.66, indicating medium to moderate 
medication adherence rate on the MAQ scale. MPC preference was significant for some 
demographic data such as ethnicity, and TM was the most preferred MPC method. 
Participants reported it was convenient to use required less time and involved the fewest 
distractions. The relationship among participants’ MPC preference and medication 
adherence yielded inconclusive results, thus reinforcing the need for further studies.  
However, this dissertation has some limitations that should be addressed in future 
studies. The first manuscript could not effectively make conclusions because the 
reviewed studies reported varying research timeframes and differences regarding 
significance of results and validity and reliability of measures. The second manuscript did 
not consider the level/severity of participants’ mental illness prior to their participating in 
the respective studies, and the conclusions about mobile phone contact providing all four 
types of social support were determined by assessing all the mobile phone contact 
methods as a single category. Further, individual mobile phone contact method (text 
message only, phone call only, or text message plus phone call) was not assessed for the 
core elements of the four types of social support described by Glanz et al. (2008).  Also, 
results from the third manuscript cannot be generalized in this population because of the 
small sample size used.  Thus, results obtained for the relationship between MPC method 
preference and medication adherence are not predictive. An intervention study is needed 
for generalizability and accurate predictability of the relationship between MPC method 
preference and medication adherence. However, none of these limitations affected the 
main findings of the dissertation regarding the usefulness of MPC methods for this 




Many lessons have been learned from this dissertation. To address medication 
non-adherence in this population, it is necessary to identify a tool that is sensitive to each 
patient’s unique needs and has validity and reliability, to accurately measure medication 
adherence in this population since there is no gold standard. Further, mobile phone 
contacts were noted to be one readily available technology that is feasible for both the 
support person and the individual with mental health challenges. Of the three methods, 
text messaging (TM) is simple to use, convenient, and inexpensive, and its use as an 
intervention to increase medication adherence in this population seems especially 
promising.  Moreover, to effectively implement MPC, it is necessary to consider 
identifying participants’ preference for an MPC method. Moreover, patient involvement 
in treatment planning and choice of an intervention helps with initiation and adherence to 
the intervention, implying that making patient preference a priority is as important as 
application of the intervention itself when seeking to support increased medication 
adherence in this population. Further, the importance of language use and cost/billing of 
MPC should not be overlooked. This dissertation seeks to inform stakeholders, especially 
policy makers, healthcare providers, and caregivers about the continual need of an 
effective means to improve medication adherence in this population.  
Future studies  
From the gaps identified in this dissertation (both integrative reviews, and the 
descriptive correlational study), there is a continual need for interventions that work to 
address the medication non-adherence menace in this population. The need for 
improvement in interventions to increase medication adherence. as well as instruments to 




even though some new measures are discovered. and MPC is noted to be promising in 
increasing medication adherence, limited studies exist for their generalizability.  
Therefore, future studies should focus on developing new generalizable medication 
adherence instruments that have validity, reliability. and sensitivity (Bright, 2016). 
Further, attention should be given to the extent to which each mobile phone contact 
method can provide social support in this population using the social support theory as a 
reference.  
This dissertation serves as a platform for the next stage of research: An 
intervention study on MPC preferences and medication adherence in mental health 
service users. This will include a sufficiently large sample size to accurately predict the 
relationship between MPC preferences and medication adherence in this population. 
Also, the extent to which each MPC method provides the four types of social support will 
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From: DONALD MORISKY [dmorisky@ucla.edu] 
Sent: Tuesday, August 29, 2017 2:46 AM 
To: Bright, Cordellia 
Subject: Re: Request for Permission to use medication adherence tool 
CAUTION: External 
 
Greetings Cordellia, and this is my first publication of my doctoral paper published in 1986.  The Morisky, 
Green and Levine Medication Adherence Scale has been cited in the medical literature over 3000 times.  It is 
in the public domain and can be translated by you with no license requirement. You can do a search of this 
article on PubMed and see how many investigators are still using this scale. Please keep me appraised of 
your adherence research. 
 




Donald Morisky, ScD, ScM, MSPH 
Research Professor 
UCLA Fielding School of Public Health  
 
On Mon, Aug 28, 2017 at 5:51 PM, Bright, Cordellia <brightco@musc.edu> wrote: 
This message was sent securely by MUSC  
 
Good afternoon Dr. Morisky, 
  
Thank you so much for your response. I contacted my school and was informed the school is unable to 
purchase the Morisky Widget MMAS License at this time. Moreover, the Morisky, Green and Levine 
Medication Adherence Scale will work perfectly for my study. I will be grateful if you grant me permission to 
use the  Morisky, Green and Levine Medication Adherence Scale as you suggested. 
  






MUSC College of Nursing 
 
From: DONALD MORISKY [dmorisky@ucla.edu] 
Sent: Sunday, August 27, 2017 3:00 PM 
To: Bright, Cordellia 
Subject: Re: Request for Permission to use medication adherence tool 
Thank you, Cordellia, for your interest in using my copyrighted intellectual property. All MMAS-8  and MMAS-4 
licenses are administered through the Morisky Widget. Beginning in 2017, I only license the MMAS-8 to organizations 
and universities, not individuals. If your University is interested in obtaining a Morisky Widget MMAS License, please 
have them contact me, otherwise, you are forbidden from using the MMAS-8., only universities and large health 
institutions are able to purchase a license. Individual licenses are no longer available. 
 
You will need a license to use my intellectual property (IP) and licenses are only provided to universities and large 
health institutions.  If you wish to use my IP, please have your university send me a note wishing to purchase a lifetime 
MMAS license to have access to all diagnostic assessment instruments including The MMAS-4 (a screening adherence 
survey), the MMAS-8 (a diagnostic assessment of medication taking behavior and WHY the patient is nonadherent), 





Widget works at morisky.org. All MMAS-8  and MMAS-4 licenses are administered through the Morisky Widget. 
 
If you cannot get your university to purchase a lifetime Morisky Widget to be used by all students, faculty, and staff in 
your university, I will give you permission to use the Morisky, Green and Levine Medication Adherence Scale.  This is 
my first publication of my doctoral paper published in 1986.  The Morisky, Green and Levine Medication Adherence 
Scale has been cited in the medical literature over 3000 times.  It is in the public domain and can be translated by you 
with no license requirement. You can do a search of this article on PubMed and see how many investigators are still 
using this scale. Please let me know if you are interested in receiving this research article. 
 




Donald Morisky, ScD, ScM, MSPH 
Research Professor 
UCLA Fielding School of Public Health 
 
On Wed, Aug 23, 2017 at 7:18 PM, Bright, Cordellia <brightco@musc.edu> wrote: 




I am a doctoral student at the Medical University of South Carolina and I am planning my dissertation study involving 
assessment of medication adherence in individuals receiving mental health services. 	
		
I am writing to seek your permission to use the eight item medication adherence scale you used in your 
study "Morisky, D. E., Ang, A., Krousel-Wood, M., Ward, H J. (2008). Predictive validity of a medication adherence 
measure in an outpatient setting. J Clin Hypertens (Greenwich) 10(5): 348–354".	
I hope to start my data collection by September 2017 and will be grateful if you grant me permission to use your tool.	
		
Thank you in advance for your consideration.	
Cordellia Bright	
PhD Candidate	








Data collection instruments for demographic/clinical data 
Study ID# ------------------------------ 






b. Female  
c. Other  
Please specify -------------- 
3. Cultural origin  
------------------------- 
Treatment information  
 
4. Primary psychiatric diagnosis 
-------------------------- 
5. Other mental health diagnoses 
-------------------------------- 
--------------------------------- 




7. History of substance use 
i. Yes  
ii. No 
 
8. Duration of primary psychiatric illness 
----------------------------- 
9. Number of psychiatric hospitalizations  
------------------------------ 












QUESTIONNAIRE FOR DEMOGRAPHIC INFORMATION 
 
Study ID ---------------------- 
 
 








3. Who is available to support you after discharge?  
--------------------------------------------------- 
 
4. Do you have problems taking medications at home?  
i. Yes 
ii. No 




If Yes, do you use the mobile phone solely by yourself or you share use of your mobile 
phone with someone? 
i. Sole usage 
ii. Shared usage 





If yes, through which means? 
i. Text messages 
ii. Phone calls 
iii. Text messages plus phone calls 
 




7. Would you like to be contacted by a service provider through mobile phone to provide 
you with support after discharge? 
 
i. Yes  






Medication adherence assessment tool 
Study ID# ------------------------------  
MORISKY, GREEN AND LEVINE MEDICATION ADHERENCE SCALE – 
MAQ 






Question  No = 0 Yes= 1 
   
1. Do you ever forget to take your medicine?   





3. When you feel better do you sometimes stop 
taking your medicine?  
  
4. Sometimes if you feel worse when you take the 









Study ID ---------------------- 
Interview Questions 
 
Many patients have trouble taking their medications at home. I want to talk to you about 
how we might be able to help you remember to take your medications at home. 
Remember, there are three mobile phone contacts delivery methods;  
 
i. TEXT MESSAGES 
ii. PHONE CALLS  
iii. TEXT MESSAGES PLUS PHONE CALLS. 
 
Please choose the options that best answers the question in your view by circling them. You 
can choose more than one answer and write in your views if they are not reflected in the 
answer choices below each question.  
 
1. What might be the benefits of receiving support through a mobile phone contact to 
remind you to take your medication?  Please circle the answer that best reflect your 
views and specify any that is not listed below in option ‘I’.  
a. I will be able to remember to take my medications. 
b. I will be able to receive advice if I cannot remember details about my 
medications. 
c. I will be able to ask questions about my treatment. 
d. I will be able stay on my medications and not just stop taking them. 
e. I will know someone cares about me. 
f. I will be more responsible since I will constantly be reminded to take my 
medications.   
g. I will not have to worry about tracking the time to take my medications. 










2. What might be the problems with receiving support through a mobile phone contact 
to remind you to take your medication? Please circle the answer that best reflect 
your views and specify any that is not listed below in option ‘f’. 
a. It will distract me.  
b. I will feel controlled. 
c. I will not have any privacy. 
d. It will cause people around me to know I am taking medications. 
e. I will be dependent on reminders and not remember to take my medications if my 
phone turns off, gets destroyed or if I do not get the reminders. 





3. If a health care provider contacts you by mobile phone, which mobile phone contact 
method would you prefer to be used?  
-------------------------------------------------- 
-------------------------------------------------- 
4. Why did you choose this mobile phone contact method? Please circle the answer 
that best reflect your views and specify any that is not listed below in option ‘I’. 
a. It is convenient 
b. It is simple to use. 
c. It is less distractive. 
d. It will require less of my time. 
e. It will provide me with more privacy. 





g. I will get someone to talk to about my problems. 
h. I will get someone to talk to about my symptoms. 
i. Other 




5. Which method would be your second choice? 
----------------------------------------------------- 
----------------------------------------------------- 
6. Why would this be your second choice? Please circle the answer that best reflect 
your views and specify any that is not listed below in option ‘I’. 
a. It is convenient 
b. It is simple to use. 
c. It is less distractive. 
d. It will require less of my time. 
e. It will provide me with more privacy 
f. I can receive advice if I am confused about my medications. 
g. I will get someone to talk to about my problems. 






7. Which method would be your last choice?  
----------------------------------------------------- 
----------------------------------------------------- 
8. Why would this be your last choice? Please circle the answer that best reflect your 
views and specify any that is not listed below in option ‘I’. 





b. It is not simple to use. 
c. It is more distractive. 
d. It will require too much of my time. 
e. It will provide me with less privacy. 
f. I will not be able to receive advice if I am confused about my medications. 
g. I will not get someone to talk to about my problems. 






9. What problems do you think might arise if you receive support through your mobile 
phone to remind you to take your medication? Please circle the answer that best 
reflect your views and specify any that is not listed below in option ‘k’. 
a. I cannot read and write in English. 
b. I may not be able to understand the message I receive. 
c. I may not receive the message/call due to network issues. 
d. I may not be able to retrieve message/text. 
e. I may not be able to read text message if the letter characters are too small. 
f. I may lack the skills of using mobile phone for the purpose of receiving 
reminders. 
g. I may feel discomfort with typing response. 
h. I will not be able to pay for the extra charge from receiving mobile phone contact. 
i. My mobile phone battery may run down. 










10. How can these problems be avoided or overcome? Please circle the answer that best 
reflect your views and specify any that is not listed below in option ‘M’. 
a. I want to receive text and phone calls in the language I understand.  
b. I would prefer the message be sent to my caregiver since I cannot read and write. 
c. The messages should be clear, simple and understandable.   
d. Use soft key options for responding to mobile phone contacts. 
e. Use on-screen number options for responding to mobile phone contacts. 
f. I would like to receive a demonstration on how to retrieve the text message/calls. 
g. I will make sure I pay my bills to get network all the time. 
h. The letters of the text message should be in big sizes for me to read easily. 
i. I would prefer to receive phone calls options since I may feel discomfort with 
typing. 
j. I would prefer to receive prepaid mobile phone contact. 
k. I want to receive the mobile phone contact based on my own preferred times. 
l. I will ensure I charge my mobile phone at all times. 





11. What other suggestions or recommendations do you want to make regarding this 
topic? 
Please specify 
----------------------------------------------------- 
----------------------------------------------------- 
------------------------------------------------------ 
